Details of Drug-Metabolizing Enzyme (DME)

General Information of DME (ID: DME0012)
DME Name	Cytochrome P450 3A5 (CYP3A5), Homo sapiens
Synonyms	Cytochrome P450 family 3 subfamily A member 5; Cytochrome P450-PCN3; CYP3A5; CYPIIIA5
Gene Name	CYP3A5
UniProt ID	CP3A5_HUMAN
Gene ID	1577
EC Number	EC: 1.14.14.1 (Click to Show/Hide the Complete EC Tree) Oxidoreductase Oxygen paired donor oxidoreductase Flavin/flavoprotein donor oxidoreductase EC: 1.14.14.1
Lineage	Species: Homo sapiens (Click to Show/Hide the Complete Species Lineage) Kingdom: Metazoa Phylum: Chordata Class: Mammalia Order: Primates Family: Hominidae Genus: Homo Species: Homo sapiens
Interactome (loading-time for this interactome depdends on the speed of web connection)
Interactions between Microbiome and DME (MICBIO) Jump to Detailed Interactome Data
Interactions between Xenobiotics and DME (XEOTIC) Jump to Detailed Interactome Data
Interactions between Host Protein and DME (HOSPPI) Jump to Detailed Interactome Data

Click to Show/Hide the Molecular/Functional Data (Sequence/Structure/Pathway/Function) of This DME
Sequence	MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNVLSYRQGLWKF DTECYKKYGKMWGTYEGQLPVLAITDPDVIRTVLVKECYSVFTNRRSLGPVGFMKSAISL AEDEEWKRIRSLLSPTFTSGKLKEMFPIIAQYGDVLVRNLRREAEKGKPVTLKDIFGAYS MDVITGTSFGVNIDSLNNPQDPFVESTKKFLKFGFLDPLFLSIILFPFLTPVFEALNVSL FPKDTINFLSKSVNRMKKSRLNDKQKHRLDFLQLMIDSQNSKETESHKALSDLELAAQSI IFIFAGYETTSSVLSFTLYELATHPDVQQKLQKEIDAVLPNKAPPTYDAVVQMEYLDMVV NETLRLFPVAIRLERTCKKDVEINGVFIPKGSMVVIPTYALHHDPKYWTEPEEFRPERFS KKKDSIDPYIYTPFGTGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLDTQG LLQPEKPIVLKVDSRDGTLSGE
Structure	5VEU
Pathway	Chemical carcinogenesis (hsa05204 )
	Drug metabolism - cytochrome P450 (hsa00982 )
	Metabolic pathways (hsa01100 )
	Metabolism of xenobiotics by cytochrome P450 (hsa00980 )
	Retinol metabolism (hsa00830 )
	Steroid hormone biosynthesis (hsa00140 )
Function	This enzyme is involved in the metabolism of steroid hormones and vitamins. It catalyzes the hydroxylation of carbon-hydrogen bonds and exhibits high catalytic activity for the formation of catechol estrogens from 17beta- estradiol (E2) and estrone (E1), namely 2-hydroxy E1 and E2. It also catalyzes 6beta-hydroxylation of the steroid hormones testosterone, progesterone, and androstenedione and the oxidative conversion of all-trans- retinol to all-trans-retinal. It further metabolizes all trans-retinoic acid (atRA) to 4-hydroxyretinoate and may play a role in hepatic atRA clearance. It is also involved in the oxidative metabolism of xenobiotics, including calcium channel blocking drug nifedipine and immunosuppressive drug cyclosporine.

Full List of Drug(s) Metabolized by This DME
Drugs Approved by FDA			Click to Show/Hide the Full List of Drugs: 228 Drugs
Thalidomide	Drug Info	Approved	Breast cancer	ICD11: 2C60	[1]
Cobicistat	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[2]
Tamoxifen citrate	Drug Info	Approved	Breast cancer	ICD11: 2C60	[3]
Yn-968D1	Drug Info	Approved	Breast cancer	ICD11: 2C60-2C6Y	[4]
Erlotinib hydrochloride	Drug Info	Approved	Lung cancer	ICD11: 2C25	[5]
Estradiol acetate	Drug Info	Approved	Acquired prion disease	ICD11: 8E01	[6]
Estradiol cypionate	Drug Info	Approved	Acquired prion disease	ICD11: 8E01	[7]
Estradiol valerate	Drug Info	Approved	Acquired prion disease	ICD11: 8E01	[8]
Estrone	Drug Info	Approved	Menopausal disorder	ICD11: GA30	[9]
Atazanavir	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[10]
Cocaine	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[11]
Pimavanserin	Drug Info	Approved	Parkinsonism	ICD11: 8A00	[12]
Ozanimod	Drug Info	Approved	Multiple sclerosis	ICD11: 8A40	[13]
Daclatasvir dihydrochloride	Drug Info	Approved	Viral hepatitis	ICD11: 1E51	[14]
Delavirdine mesylate	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[8]
Prednisolone	Drug Info	Approved	Multiple myeloma	ICD11: 2A83	[15]
Amlodipine besylate	Drug Info	Approved	Essential hypertension	ICD11: BA00	[16]
Ibrutinib	Drug Info	Approved	Mantle cell lymphoma	ICD11: 2A85	[17]
Loxoprofen gel	Drug Info	Approved	Inflammation	ICD11: 1A00-CA43	[18]
Montelukast sodium	Drug Info	Approved	Asthma	ICD11: CA23	[19], [20]
Montelukast sodium	Drug Info	Approved	Asthma	ICD11: CA23	[20]
Progesterone	Drug Info	Approved	Premature labour	ICD11: JB00	[21]
Acalabrutinib	Drug Info	Approved	Mantle cell lymphoma	ICD11: 2A85	[22]
Crizotinib	Drug Info	Approved	Lung cancer	ICD11: 2C25	[23]
Imatinib mesylate	Drug Info	Approved	Chronic myelogenous leukaemia	ICD11: 2A20	[24]
Lidocaine	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[8]
Metronidazole	Drug Info	Approved	Amebiasis	ICD11: 1A36	[25]
Temsirolimus	Drug Info	Approved	Renal cell carcinoma	ICD11: 2C90	[8]
Cannabidiol	Drug Info	Approved	Lennox-Gastaut syndrome	ICD11: 8A62	[26]
Ciclosporin	Drug Info	Approved	Viral hepatitis	ICD11: 1E51	[27]
Ciclosporin	Drug Info	Approved	Viral hepatitis	ICD11: 1E51	[28]
Doravirine	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[29]
Ethinyl estradiol	Drug Info	Approved	Menopausal disorder	ICD11: GA30	[30]
Ifosfamide	Drug Info	Approved	Lung cancer	ICD11: 2C25	[31]
Lapatinib ditosylate	Drug Info	Approved	Breast cancer	ICD11: 2C60	[5]
Mycophenolate mofetil	Drug Info	Approved	Crohn disease	ICD11: DD70	[32]
Sunitinib malate	Drug Info	Approved	Renal cell carcinoma	ICD11: 2C90	[8]
Sunitinib malate	Drug Info	Approved	Renal cell carcinoma	ICD11: 2C90	[33]
Tacrolimus	Drug Info	Approved	Ulcerative colitis	ICD11: DD71	[34]
Tretinoin	Drug Info	Approved	Acne vulgaris	ICD11: ED80	[35]
Valproic acid	Drug Info	Approved	Epilepsy	ICD11: 8A60	[19]
Cabazitaxel	Drug Info	Approved	Breast cancer	ICD11: 2C60	[36]
Disulfiram	Drug Info	Approved	Alcohol dependence	ICD11: 6C40	[37]
Enzalutamide	Drug Info	Approved	Prostate cancer	ICD11: 2C82	[38]
Oxycodone hydrochloride	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[39]
Pravastatin	Drug Info	Approved	Dyslipidaemia	ICD11: 5C81	[40]
Rivaroxaban	Drug Info	Approved	Deep vein thrombosis	ICD11: BD71	[41]
Sirolimus	Drug Info	Approved	Lymphangioleiomyomatosis	ICD11: CB07	[8]
Apomorphine	Drug Info	Approved	Parkinsonism	ICD11: 8A00	[42]
Beclomethasone dipropionate	Drug Info	Approved	Allergic rhinitis	ICD11: CA08	[43], [44]
Beclomethasone dipropionate	Drug Info	Approved	Allergic rhinitis	ICD11: CA08	[45]
Clomiphene citrate	Drug Info	Approved	Female infertility	ICD11: GA31	[46]
Deoxycholic acid	Drug Info	Approved	Obesity	ICD11: 5B81	[47]
Hydrocortisone	Drug Info	Approved	Uncontrolled gout	ICD11: FA25	[48]
Indinavir sulfate	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[49]
Osimertinib	Drug Info	Approved	Lung cancer	ICD11: 2C25	[50]
Perampanel	Drug Info	Approved	Focal seizure	ICD11: 8A68	[51]
Ponesimod	Drug Info	Approved	Multiple sclerosis	ICD11: 8A40	[52]
Ponesimod	Drug Info	Approved	Multiple sclerosis	ICD11: 8A40	[53]
Quinine sulfate	Drug Info	Approved	Malaria	ICD11: 1F40	[8]
Telithromycin	Drug Info	Approved	Bronchitis	ICD11: CA20	[54]
Teniposide	Drug Info	Approved	Acute lymphoblastic leukemia	ICD11: 2B33	[55]
Ticagrelor	Drug Info	Approved	Cerebral stroke	ICD11: 8B11	[56], [57]
Tucatinib	Drug Info	Approved	HER2-positive breast cancer	ICD11: 2C60-2C6Y	[58]
Alfentanil	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[59]
Arteether	Drug Info	Approved	Malaria	ICD11: 1F40-1F45	[60]
Axitinib	Drug Info	Approved	Renal cell carcinoma	ICD11: 2C90	[61]
Cisapride	Drug Info	Approved	Gastro-oesophageal reflux disease	ICD11: DA22	[62]
Dextromethorphan hydrobromide	Drug Info	Approved	Atherosclerosis	ICD11: BA80	[63]
Diazepam	Drug Info	Approved	Epilepsy	ICD11: 8A60	[64]
Diphenylpyraline	Drug Info	Approved	Allergy	ICD11: 4A80	[65]
Finasteride	Drug Info	Approved	Prostatic hyperplasia	ICD11: GA90	[8]
Flutamide	Drug Info	Approved	Prostate cancer	ICD11: 2C82	[66]
Haloperidol decanoate	Drug Info	Approved	Agitation/aggression	ICD11: 6D86	[67]
Lansoprazole	Drug Info	Approved	Duodenal ulcer	ICD11: DA63	[68]
Lasofoxifene	Drug Info	Approved	Osteoporosis	ICD11: FB83	[69]
Lasofoxifene	Drug Info	Approved	Osteoporosis	ICD11: FB83	[70]
Levonorgestrel	Drug Info	Approved	Menorrhagia	ICD11: GA20	[71]
Nateglinide	Drug Info	Approved	Diabetes mellitus	ICD11: 5A10	[8]
Nevirapine	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[19]
Norethindrone acetate	Drug Info	Approved	Menorrhagia	ICD11: GA20	[72]
Ondansetron	Drug Info	Approved	Gastritis	ICD11: DA42	[73]
Propranolol hydrochloride	Drug Info	Approved	Migraine	ICD11: 8A80	[74]
Trazodone hydrochloride	Drug Info	Approved	Depression	ICD11: 6A71	[8]
Verapamil hydrochloride	Drug Info	Approved	Essential hypertension	ICD11: BA00	[75]
Amitriptyline hydrochloride	Drug Info	Approved	Depression	ICD11: 6A71	[76]
Amprenavir	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[77]
Artemether	Drug Info	Approved	Malaria	ICD11: 1F40	[78]
Bromfenac	Drug Info	Approved	Cataract	ICD11: 9B10	[79]
Buspirone	Drug Info	Approved	Anxiety disorder	ICD11: 6B00	[80]
Carbamazepine	Drug Info	Approved	Epilepsy	ICD11: 8A60	[81]
Cenobamate	Drug Info	Approved	Focal seizure	ICD11: 8A68	[82]
Cortisone acetate	Drug Info	Approved	Prostate cancer	ICD11: 2C82	[83]
Dasatinib	Drug Info	Approved	Chronic myelogenous leukaemia	ICD11: 2A20	[5]
Diltiazem hydrochloride	Drug Info	Approved	Essential hypertension	ICD11: BA00	[84]
Doxorubicin	Drug Info	Approved	Breast cancer	ICD11: 2C60	[85]
Dronedarone hydrochloride	Drug Info	Approved	Atrial fibrillation	ICD11: BC81	[86]
Fluoxetine hydrochloride	Drug Info	Approved	Depression	ICD11: 6A71	[87]
Fluvastatin sodium	Drug Info	Approved	Hypertriglyceridaemia	ICD11: 5C80	[88]
Istradefylline	Drug Info	Approved	Parkinsonism	ICD11: 8A00	[89]
Ivermectin	Drug Info	Approved	Onchocerciasis	ICD11: 1F6A	[90]
Letermovir	Drug Info	Approved	Cytomegalovirus infection	ICD11: 1D82	[91]
Midazolam hydrochloride	Drug Info	Approved	Anxiety disorder	ICD11: 6B00	[92]
Phenytoin	Drug Info	Approved	Epilepsy	ICD11: 8A60	[93]
Rilpivirine hydrochloride	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[94]
Simvastatin	Drug Info	Approved	Dyslipidaemia	ICD11: 5C81	[95]
Simvastatin	Drug Info	Approved	Dyslipidaemia	ICD11: 5C81	[96]
Vismodegib	Drug Info	Approved	Melanoma	ICD11: 2C30	[97], [98], [99]
Zolpidem tartrate	Drug Info	Approved	Insomnia	ICD11: 7A00	[100]
Anastrozole	Drug Info	Approved	Breast cancer	ICD11: 2C60	[101]
Argatroban	Drug Info	Approved	Thrombosis	ICD11: DB61	[102]
Atorvastatin calcium	Drug Info	Approved	Dyslipidaemia	ICD11: 5C81	[103]
Azelastine	Drug Info	Approved	Allergic rhinitis	ICD11: CA08	[104]
Buprenorphine hydrochloride	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[105]
Clarithromycin	Drug Info	Approved	Pneumocystis pneumonia	ICD11: CA40	[8]
Clofazimine	Drug Info	Approved	Crohn disease	ICD11: DD70	[106]
Clonidine	Drug Info	Approved	Essential hypertension	ICD11: BA00	[107]
Doxapram hydrochloride	Drug Info	Approved	Chronic obstructive pulmonary disease	ICD11: CA22	[108]
Fentanyl citrate	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[109]
Loxapine succinate	Drug Info	Approved	Schizophrenia	ICD11: 6A20	[110]
Lurbinectedin	Drug Info	Approved	Lung cancer	ICD11: 2C25	[111]
Mifepristone	Drug Info	Approved	Cushing syndrome	ICD11: 5A70	[112]
Nalmefene	Drug Info	Approved	Opiate dependence	ICD11: 6C43	[113]
Nisoldipine	Drug Info	Approved	Essential hypertension	ICD11: BA00	[8]
Omeprazole	Drug Info	Approved	Gastro-oesophageal reflux disease	ICD11: DA22	[114]
Oxycodone	Drug Info	Approved	Pain	ICD11: MG30-MG3Z	[115]
Paroxetine hydrochloride	Drug Info	Approved	Depression	ICD11: 6A71	[116]
Pimozide	Drug Info	Approved	Schizophrenia	ICD11: 6A20	[8]
Ponatinib hydrochloride	Drug Info	Approved	Acute lymphoblastic leukemia	ICD11: 2B33	[117]
Prochlorperazine	Drug Info	Approved	Functional nausea/vomiting	ICD11: DD90	[118]
Quetiapine fumarate	Drug Info	Approved	Schizophrenia	ICD11: 6A20	[119]
Ritonavir	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[8]
Saquinavir mesylate	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[120]
Sulfasalazine	Drug Info	Approved	Rheumatoid arthritis	ICD11: FA20	[121]
Testosterone undecanoate	Drug Info	Approved	Hypogonadism	ICD11: 5A61	[92]
Triazolam	Drug Info	Approved	Insomnia	ICD11: 7A00	[92]
Vortioxetine hydrobromide	Drug Info	Approved	Depression	ICD11: 6A71	[122]
Acetaminophen	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[123]
Alprazolam	Drug Info	Approved	Anxiety disorder	ICD11: 6B00	[124]
Apixaban	Drug Info	Approved	Deep vein thrombosis	ICD11: BD71	[125]
Aripiprazole lauroxil	Drug Info	Approved	Schizophrenia	ICD11: 6A20	[8]
Avapritinib	Drug Info	Approved	Gastrointestinal stromal tumour	ICD11: 2B5B	[126]
Chlorpheniramine	Drug Info	Approved	Allergic rhinitis	ICD11: CA08	[8]
Clonazepam	Drug Info	Approved	Epilepsy	ICD11: 8A60	[127]
Docetaxel	Drug Info	Approved	Breast cancer	ICD11: 2C60	[8]
Dutasteride	Drug Info	Approved	Prostatic hyperplasia	ICD11: GA90	[128]
Dutasteride	Drug Info	Approved	Prostatic hyperplasia	ICD11: GA90	[129]
Etoposide	Drug Info	Approved	Lung cancer	ICD11: 2C25	[130]
Gefitinib	Drug Info	Approved	Lung cancer	ICD11: 2C25	[131]
Iloperidone	Drug Info	Approved	Schizophrenia	ICD11: 6A20	[132]
Irinotecan hydrochloride	Drug Info	Approved	Colon cancer	ICD11: 2B90	[133]
Lenvatinib	Drug Info	Approved	Thyroid cancer	ICD11: 2D10	[134]
Levomethadyl acetate hydrochloride	Drug Info	Approved	Opiate dependence	ICD11: 6C43	[8]
Losartan potassium	Drug Info	Approved	Essential hypertension	ICD11: BA00	[63]
Lovastatin	Drug Info	Approved	Hypertriglyceridaemia	ICD11: 5C80	[135]
Methadone	Drug Info	Approved	Anaesthesia	ICD11: 8E22	[136]
Mycophenolic acid	Drug Info	Approved	Crohn disease	ICD11: DD70	[137], [138]
Mycophenolic acid	Drug Info	Approved	Crohn disease	ICD11: DD70	[139]
Nelfinavir mesylate	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[120]
Nimodipine	Drug Info	Approved	Cerebral vasospasm	ICD11: BA85	[140]
Paclitaxel	Drug Info	Approved	Ovarian cancer	ICD11: 2C73	[8]
Palonosetron hydrochloride	Drug Info	Approved	Functional nausea/vomiting	ICD11: DD90	[141]
Phenelzine	Drug Info	Approved	Depression	ICD11: 6A71	[142]
Phenobarbital	Drug Info	Approved	Epilepsy	ICD11: 8A60	[143]
Riociguat	Drug Info	Approved	Pulmonary hypertension	ICD11: BB01	[144]
Sorafenib	Drug Info	Approved	Renal cell carcinoma	ICD11: 2C90	[8]
Voriconazole	Drug Info	Approved	Candidiasis	ICD11: 1F23	[145], [146]
Zaleplon	Drug Info	Approved	Insomnia	ICD11: 7A00	[8]
Ambrisentan	Drug Info	Approved	Pulmonary hypertension	ICD11: BB01	[147]
Armodafinil	Drug Info	Approved	Obstructive sleep apnea	ICD11: 7A41	[148]
Boceprevir	Drug Info	Approved	Viral hepatitis	ICD11: 1E51	[149]
Cerivastatin sodium	Drug Info	Approved	Hypertriglyceridaemia	ICD11: 5C80	[8]
Cilostazol	Drug Info	Approved	Arteriosclerosis obliterans	ICD11: BD40	[150]
Clindamycin	Drug Info	Approved	Acne vulgaris	ICD11: ED80	[151]
Clopidogrel bisulfate	Drug Info	Approved	Acute coronary syndrome	ICD11: BA4Z	[152]
Dapsone	Drug Info	Approved	Pneumocystis pneumonia	ICD11: CA40	[8]
Eplerenone	Drug Info	Approved	Ventricular dysfunction	ICD11: BD13	[153]
Granisetron hydrochloride	Drug Info	Approved	Functional nausea/vomiting	ICD11: DD90	[154]
Isavuconazole	Drug Info	Approved	Allergic bronchopulmonary aspergillosis	ICD11: CA82	[155]
Ivacaftor	Drug Info	Approved	Cystic fibrosis	ICD11: CA25	[156]
Loratadine	Drug Info	Approved	Allergic rhinitis	ICD11: CA08	[157]
Megestrol acetate	Drug Info	Approved	Breast cancer	ICD11: 2C60	[158]
Mephenytoin	Drug Info	Approved	Epilepsy	ICD11: 8A60	[159]
Nifedipine	Drug Info	Approved	Angina pectoris	ICD11: BA40	[92]
Oxazepam	Drug Info	Approved	Anxiety disorder	ICD11: 6B00	[160]
Paliperidone	Drug Info	Approved	Bipolar disorder	ICD11: 6A60	[161]
Pentamidine isethionate	Drug Info	Approved	Pneumocystis pneumonia	ICD11: CA40	[162]
Salmeterol xinafoate	Drug Info	Approved	Asthma	ICD11: CA23	[8]
Secnidazole	Drug Info	Approved	Amebiasis	ICD11: 1A36	[163]
Sildenafil citrate	Drug Info	Approved	Erectile dysfunction	ICD11: HA01	[164]
Temazepam	Drug Info	Approved	Insomnia	ICD11: 7A00	[165]
Voxelotor	Drug Info	Approved	Sickle-cell anaemia	ICD11: 3A51	[166]
Zonisamide	Drug Info	Approved	Epilepsy	ICD11: 8A60	[167]
Aztreonam	Drug Info	Approved	Cystic fibrosis	ICD11: CA25	[168]
Bimatoprost	Drug Info	Approved	Glaucoma	ICD11: 9C61	[169]
Chloroquine	Drug Info	Approved	Malaria	ICD11: 1F40	[170]
Chloroquine	Drug Info	Approved	Malaria	ICD11: 1F40	[171]
Erythromycin stearate	Drug Info	Approved	Acute upper respiratory infection	ICD11: CA07	[172]
Felodipine	Drug Info	Approved	Essential hypertension	ICD11: BA00	[8]
Fluticasone furoate	Drug Info	Approved	Allergic rhinitis	ICD11: CA08	[173]
Fluticasone propionate	Drug Info	Approved	Asthma	ICD11: CA23	[174]
Fluticasone propionate	Drug Info	Approved	Asthma	ICD11: CA23	[175]
Halofantrine	Drug Info	Approved	Malaria	ICD11: 1F40	[176]
Hydroxyprogesterone caproate	Drug Info	Approved	Uterine cancer	ICD11: 2C76	[177]
Hydroxyzine	Drug Info	Approved	Anxiety disorder	ICD11: 6B00	[178]
Isavuconazonium	Drug Info	Approved	Allergic bronchopulmonary aspergillosis	ICD11: CA82	[155]
Lonafarnib	Drug Info	Approved	Progeria	ICD11: LD2B	[179]
Lorlatinib	Drug Info	Approved	Lung cancer	ICD11: 2C25	[180]
Nortriptyline hydrochloride	Drug Info	Approved	Depression	ICD11: 6A71	[181]
Oxybutynin chloride	Drug Info	Approved	Overactive bladder	ICD11: GC50	[182]
Pimecrolimus	Drug Info	Approved	Atopic dermatitis	ICD11: EA80	[183]
Praziquantel	Drug Info	Approved	Schistosomiasis	ICD11: 1F86	[184]
Ripretinib	Drug Info	Approved	Gastrointestinal stromal tumour	ICD11: 2B5B	[185]
Risperidone	Drug Info	Approved	Schizophrenia	ICD11: 6A20	[161]
Romidepsin	Drug Info	Approved	Cutaneous T-cell lymphoma	ICD11: 2B01	[186]
Saxagliptin hydrochloride	Drug Info	Approved	Diabetes mellitus	ICD11: 5A10	[187]
Tadalafil	Drug Info	Approved	Erectile dysfunction	ICD11: HA01	[188]
Tenapanor	Drug Info	Approved	Hyperphosphatemia	ICD11: 5C64	[189]
Testosterone cypionate	Drug Info	Approved	Testosterone deficiency	ICD11: 5A81	[92]
Testosterone enanthate	Drug Info	Approved	Testosterone deficiency	ICD11: 5A81	[92]
Triamcinolone diacetate	Drug Info	Approved	Allergy	ICD11: 4A80	[190]
Vardenafil hydrochloride	Drug Info	Approved	Erectile dysfunction	ICD11: HA01	[164]
Vinblastine sulfate	Drug Info	Approved	Breast cancer	ICD11: 2C60	[85]
Vincristine sulfate	Drug Info	Approved	Acute lymphoblastic leukemia	ICD11: 2B33	[191]
Zalcitabine	Drug Info	Approved	Human immunodeficiency virus infection	ICD11: 1C60	[192]
Dexamethasone acetate	Drug Info	Approved	Rheumatoid arthritis	ICD11: FA20	[193]
Guanfacine	Drug Info	Phase 4	Hepatocellular carcinoma	ICD11: 2C12	[197]
Ingrezza	Drug Info	Phase 4	Dyskinesia	ICD11: 8A02	[201]
Drugs in Phase 4 Clinical Trial			Click to Show/Hide the Full List of Drugs: 11 Drugs
Ethinylestradiol propanesulfonate	Drug Info	Phase 4	Prostate cancer	ICD11: 2C82	[194], [195]
Glibenclamide	Drug Info	Phase 4	Diabetes mellitus	ICD11: 5A10	[196]
Vonoprazan	Drug Info	Phase 4	Gastro-oesophageal reflux disease	ICD11: DA22	[198]
Zotepine	Drug Info	Phase 4	Schizophrenia	ICD11: 6A20	[199]
Astemizole	Drug Info	Phase 4	Allergic rhinitis	ICD11: CA08	[8]
Terfenadine	Drug Info	Phase 4	Allergy	ICD11: 4A80	[8]
Chlorphenamine	Drug Info	Phase 4	Allergy	ICD11: 4A80	[8]
Benidipine	Drug Info	Phase 4	Diabetic nephropathy	ICD11: GB61	[200]
Rupatadine	Drug Info	Phase 4	Allergy	ICD11: 4A80	[202]
Beclabuvir	Drug Info	Phase 4	Viral hepatitis	ICD11: 1E51	[203]
Tegafur	Drug Info	Phase 4	Colon cancer	ICD11: 2B90	[204]
Drugs in Phase 3 Clinical Trial			Click to Show/Hide the Full List of Drugs: 30 Drugs
E-3A	Drug Info	Phase 3	Turner syndrome	ICD11: LD50	[8]
Selumetinib	Drug Info	Phase 3	Neurofibromatosis	ICD11: LD2D	[205]
EPIANDROSTERONE	Drug Info	Phase 3	Discovery agent	ICD: N.A.	[206]
BMS-650032	Drug Info	Phase 3	Viral hepatitis	ICD11: 1E51	[207]
Tivantinib	Drug Info	Phase 3	Solid tumour/cancer	ICD11: 2A00-2F9Z	[208]
BPI-2009	Drug Info	Phase 3	Lung cancer	ICD11: 2C25	[209]
KW-5338	Drug Info	Phase 3	Gastroparesis	ICD11: DA41	[8]
NE-10064	Drug Info	Phase 3	Cardiac arrhythmia	ICD11: BC65	[210]
NSC-122758	Drug Info	Phase 3	Vitamin deficiency	ICD11: 5B55	[35]
NSC-122758	Drug Info	Phase 3	Vitamin deficiency	ICD11: 5B55	[35], [211]
SCH-417690	Drug Info	Phase 3	Human immunodeficiency virus infection	ICD11: 1C60	[19]
GW-1000	Drug Info	Phase 3	Cerebral vasospasm	ICD11: BA85	[26]
MLN4924	Drug Info	Phase 3	Myelodysplastic syndrome	ICD11: 2A37	[212]
AK-602	Drug Info	Phase 3	Human immunodeficiency virus infection	ICD11: 1C60	[213]
TAK-875	Drug Info	Phase 3	Diabetes mellitus	ICD11: 5A10	[214]
VX-661	Drug Info	Phase 3	Cystic fibrosis	ICD11: CA25	[215]
ABT-773	Drug Info	Phase 3	Pneumocystis pneumonia	ICD11: CA40	[216]
BRN-0077922	Drug Info	Phase 3	Influenza virus infection	ICD11: 1E30	[217]
Hydroxychloroquine	Drug Info	Phase 3	Malaria	ICD11: 1F40-1F45	[171]
LY-450139	Drug Info	Phase 3	Alzheimer disease	ICD11: 8A20	[218]
CR-2017	Drug Info	Phase 3	Irritable bowel syndrome	ICD11: DD91	[219]
Fenfluramine	Drug Info	Phase 3	Dravet syndrome	ICD11: 8A61-8A6Z	[220]
Imatinib	Drug Info	Phase 3	Mantle cell lymphoma	ICD11: 2A85	[24]
CQA 206-291	Drug Info	Phase 3	Parkinsonism	ICD11: 8A00	[221]
DUP-996	Drug Info	Phase 3	Cognitive impairment	ICD11: 6D71	[222]
Ganaxolone	Drug Info	Phase 3	Complex partial seizure	ICD11: 8A61-8A6Z	[223]
RO-7-0207	Drug Info	Phase 3	Colon cancer	ICD11: 2B90	[224]
Sildenafil	Drug Info	Phase 3	Erectile dysfunction	ICD11: HA00-HA01	[188]
Al3-818	Drug Info	Phase 3	Leiomyosarcoma	ICD11: 2B58	[225]
Atorvastatin	Drug Info	Phase 3	Hypertriglyceridaemia	ICD11: 5C80	[226]
Drugs in Phase 2 Clinical Trial			Click to Show/Hide the Full List of Drugs: 27 Drugs
Verapamil	Drug Info	Phase 2/3	Hypertension	ICD11: BA00-BA04	[75]
Pexacerfont	Drug Info	Phase 2/3	Anxiety disorder	ICD11: 6B00-6B0Z	[227]
DA-8159	Drug Info	Phase 2/3	Pulmonary hypertension	ICD11: BB01	[228]
Fexinidazole	Drug Info	Phase 2/3	Trypanosomiasis	ICD11: 1D51-1F53	[229], [230]
Fexinidazole	Drug Info	Phase 2/3	Trypanosomiasis	ICD11: 1D51-1F53	[230]
HOE-239	Drug Info	Phase 2/3	Trypanosomiasis	ICD11: 1F51	[230]
Lilly-112531	Drug Info	Phase 2/3	Diffuse large B-cell lymphoma	ICD11: 2A81	[231]
Leniolisib	Drug Info	Phase 2	Sjogren syndrome	ICD11: 4A43	[232]
ABT-450	Drug Info	Phase 2	Hepatitis C virus infection	ICD11: 1E50-1E51	[233], [234]
Paritaprevir	Drug Info	Phase 2	Hepatitis C virus infection	ICD11: 1E50-1E51	[234]
PF-06463922	Drug Info	Phase 2	Lung cancer	ICD11: 2C25	[235]
AZD-2014	Drug Info	Phase 2	Brain cancer	ICD11: 2A00	[236]
CBL-0102	Drug Info	Phase 2	Creutzfeldt-Jakob disease	ICD11: 8E02	[237]
AR-67	Drug Info	Phase 2	Brain cancer	ICD11: 2A00	[238]
AZD2624	Drug Info	Phase 2	Multiple sclerosis	ICD11: 8A40	[239]
EBP-994	Drug Info	Phase 2	Progeria	ICD11: LD2B	[179]
Telapristone	Drug Info	Phase 2	Endometriosis	ICD11: GA10	[240]
AZD-2327	Drug Info	Phase 2	Anxiety disorder	ICD11: 6B00-6B0Z	[241]
GS-5806	Drug Info	Phase 2	Respiratory syncytial virus infection	ICD11: 1C80	[242]
MKC-442	Drug Info	Phase 2	Human immunodeficiency virus infection	ICD11: 1C60	[243]
Nuplazid	Drug Info	Phase 2	Alzheimer disease	ICD11: 8A20	[244]
PF-04937319	Drug Info	Phase 2	Type-2 diabetes	ICD11: 5A11	[245]
TAK-063	Drug Info	Phase 2	Schizophrenia	ICD11: 6A20	[246]
TAK-272	Drug Info	Phase 2	Type-2 diabetes	ICD11: 5A11	[247]
CC-220	Drug Info	Phase 2	Sarcoidosis	ICD11: 4B20	[248]
Encequidar	Drug Info	Phase 2	Metastatic breast cancer	ICD11: 2C60-2C6Y	[249]
SHR-1020	Drug Info	Phase 2	Breast cancer	ICD11: 2C60	[250]
Drugs in Phase 1 Clinical Trial			Click to Show/Hide the Full List of Drugs: 17 Drugs
CB-3304	Drug Info	Phase 1/2	Chronic lymphocytic leukaemia	ICD11: 2A82	[251]
CC-223	Drug Info	Phase 1/2	Lung cancer	ICD11: 2C25	[252]
TMC-120	Drug Info	Phase 1/2	Human immunodeficiency virus infection	ICD11: 1C60	[253]
TJN-324	Drug Info	Phase 1/2	Essential hypertension	ICD11: BA00	[8]
STX 64	Drug Info	Phase 1	Prostate cancer	ICD11: 2C82	[254]
AST-1306	Drug Info	Phase 1	Solid tumour/cancer	ICD11: 2A00-2F9Z	[255]
BE-14348A	Drug Info	Phase 1	Viral hepatitis	ICD11: 1E51	[256]
H3B-6545	Drug Info	Phase 1	Breast cancer	ICD11: 2C60	[257]
PPI-2458	Drug Info	Phase 1	Diabetes mellitus	ICD11: 5A10	[258]
Alvespimycin hydrochloride	Drug Info	Phase 1	Ovarian cancer	ICD11: 2C73	[259]
Benzoylphenylurea	Drug Info	Phase 1	Solid tumour/cancer	ICD11: 2A00-2F9Z	[260], [261]
DA-1229	Drug Info	Phase 1	Type-2 diabetes	ICD11: 5A11	[262]
BRN-3224996	Drug Info	Phase 1	Allergy	ICD11: 4A80	[48]
CBT-1	Drug Info	Phase 1	Histiocytic sarcoma	ICD11: 2B31	[263]
H3B-6527	Drug Info	Phase 1	Hepatocellular carcinoma	ICD11: 2C12	[264]
BRN-0498823	Drug Info	Phase 1	Essential hypertension	ICD11: BA00	[8]
ITX-5061	Drug Info	Phase 1	Human immunodeficiency virus infection	ICD11: 1C60	[265]
Discontinued/withdrawn Drugs			Click to Show/Hide the Full List of Drugs: 5 Drugs
AZD0328	Drug Info	Discontinued in Phase 2	Alzheimer disease	ICD11: 8A20	[266]
Perillyl alcohol	Drug Info	Discontinued in Phase 2	Solid tumour/cancer	ICD11: 2A00-2F9Z	[267]
ABT-107	Drug Info	Discontinued in Phase 1	Attention deficit hyperactivity disorder	ICD11: 6A05	[268]
CJ-11974	Drug Info	Discontinued	Irritable bowel syndrome	ICD11: DD91	[269]
Octopamine	Drug Info	Discontinued	Thrombosis	ICD11: DB61	[109]
Preclinical/investigative Agents			Click to Show/Hide the Full List of Drugs: 3 Drugs
Cis-4-hydroxytamoxifen	Drug Info	Investigative	Discovery agent	ICD: N.A.	[270]
Paraoxon	Drug Info	Investigative	Discovery agent	ICD: N.A.	[271]
Erythromycin salnacedin	Drug Info	Investigative	Discovery agent	ICD: N.A.	[172]

Full List of Metabolic Reactions (MR) Catalyzed by This DME

MR ID	Reactant	Product	MR Type	Source Drug	REF
MR011470	ABT-107	ABT-107 Metabolite M2	Unclear - Unclear	ABT-107	[268]
MR000122	Alfentanil	Noralfentanil	Oxidation - N-Dealkylation	Alfentanil	[272]
MR009781	17-DMAG M2	17-DMAG M6	Oxidation - Hydroxylation	Alvespimycin hydrochloride	[259]
MR009779	Alvespimycin hydrochloride	17-DMAG M2	Oxidation - Hydroxylation	Alvespimycin hydrochloride	[259]
MR009782	Alvespimycin hydrochloride	17-DMAG M1	Oxidation - Hydroxylation	Alvespimycin hydrochloride	[259]
MR009783	Alvespimycin hydrochloride	17-DMAG M3	Oxidation - Demethylation	Alvespimycin hydrochloride	[259]
MR009784	Alvespimycin hydrochloride	17-DMAG M4	Oxidation - Demethylation	Alvespimycin hydrochloride	[259]
MR009849	Ambrisentan	4-hydroxymethyl?ambrisentan	Oxidation - Oxidation	Ambrisentan	[147], [273]
MR000228	Amprenavir	Amprenavir metabolite M2	Unclear - Unclear	Amprenavir	[77]
MR000229	Amprenavir	Amprenavir metabolite M3	Unclear - Unclear	Amprenavir	[77]
MR000231	Amprenavir	Amprenavir metabolite M5	Unclear - Unclear	Amprenavir	[77]
MR000237	Anastrozole	Hydroxyanastrozole	Oxidation - Hydroxylation	Anastrozole	[101]
MR000248	Apixaban	Apixaban M2 metabolite	Oxidation - O-Demethylation	Apixaban	[274], [125]
MR000249	Apixaban	Apixaban M4/7 metabolite	Oxidation - Hydroxylation	Apixaban	[274], [125]
MR000256	Apomorphine	Norapomorphine	Oxidation - N-Demethylation	Apomorphine	[42]
MR011561	AR-67	AR-67 hypothesize	Unclear - Unclear	AR-67	[238]
MR000294	Armodafinil	Modafinil sulfone	Unclear - Unclear	Armodafinil	[275]
MR008681	Arteether	Dihydroqinghaosu (DQHS)	Oxidation - Deethylation	Arteether	[60], [276]
MR000298	Artemether	Dihydroartemisinin	Oxidation - Oxidation	Artemether	[277]
MR009785	AST-1306	Allitinib M1	Oxidation - O-dealkylation	AST-1306	[255]
MR009797	AST-1306	Allitinib M10	Unclear - Unclear	AST-1306	[255]
MR005429	Avapritinib	M690	Conjugation - Hydroxy glucuronidation	Avapritinib	[126]
MR009891	Axitinib	Axitinib Metabolite M14	Unclear - Unclear	axitinib	[278]
MR009885	Axitinib	Axitinib Metabolite M12	Unclear - Unclear	axitinib	[278]
MR009889	Axitinib	Axitinib Metabolite M8b	Unclear - Unclear	axitinib	[278]
MR009886	Axitinib Metabolite M12	Axitinib Metabolite M9	Unclear - Unclear	axitinib	[278]
MR009887	Axitinib Metabolite M12	Axitinib Metabolite M15	Unclear - Unclear	axitinib	[278]
MR007285	AZD-2014	Unclear	Unclear - Unclear	AZD-2014	[279]
MR012382	AZD-2327	N-deethylated AZD-2327	Oxidation - N-deethylation	AZD-2327	[241]
MR009369	AZD0328	AZD0328 Metabolite M6	Oxidation - N-oxidation	AZD0328	[266]
MR011562	AZD2624	AZD2624 Metabolite M1	Unclear - Unclear	AZD2624	[239]
MR011563	AZD2624	AZD2624 Metabolite M2	Unclear - Unclear	AZD2624	[239]
MR003199	Barnidipine	Barnidipine metabolite M-1	Oxidation - N-Debenzylization	Barnidipine	[280]
MR003200	Barnidipine	Barnidipine metabolite M-8	Oxidation - Oxidation	Barnidipine	[280]
MR003190	Barnidipine metabolite M-1	Barnidipine metabolite M-3	Hydrolysis - Hydrolysis	Barnidipine	[280]
MR003193	Barnidipine metabolite M-3	Barnidipine metabolite M-4	Oxidation - Oxidation	Barnidipine	[280]
MR003198	Barnidipine metabolite M-8	Barnidipine metabolite M-2	Oxidation - N-Debenzylization	Barnidipine	[280]
MR003839	BE-14348A	Eriodictyol	Oxidation - Hydrolyzationn	BE-14348A	[256]
MR003841	BE-14348A	Apigenin	Oxidation - Dehydrogenation	BE-14348A	[256]
MR000351	Beclabuvir	BCV M1	Oxidation - N-Demethylation	Beclabuvir	[203]
MR009246	Beclomethasone dipropionate	Beclomethasone-17-monopropionate (17-BMP)	Hydrolysis - Hydrolysis	Beclomethasone dipropionate	[281]
MR009251	Beclomethasone dipropionate	Beclomethasone-21-monopropionate (21-BMP)	Hydrolysis - Hydrolysis	Beclomethasone dipropionate	[45]
MR009253	Beclomethasone dipropionate	6beta-OH-BDP	Unclear - Unclear	Beclomethasone dipropionate	[282]
MR009254	Beclomethasone dipropionate	Delta6-BDP	Unclear - Unclear	Beclomethasone dipropionate	[282]
MR003037	Benidipine	N-desbenzylbenidipine	Hydrolysis - Hydrolysis; Reduction	Benidipine	[200]
MR003038	Benidipine	Dehydrobenidipine	Unclear - Unclear	Benidipine	[200]
MR010376	Benzoylphenylurea	MmBPU	Oxidation - Desmethylation	Benzoylphenylurea	[260], [261]
MR000384	Asunaprevir metabolite M6	Asunaprevir metabolite M9	Oxidation - Oxidation	BMS-650032	[203], [283]
MR000389	BMS-650032	Asunaprevir metabolite M6	Oxidation - O-Demethylation	BMS-650032	[203], [283]
MR000394	BMS-650032	Asunaprevir metabolite M3,5,7	Oxidation - Monohydroxylation	BMS-650032	[203], [283]
MR006805	Boceprevir	Boceprevir metabolite M28	Multi-steps Reaction - Oxidationn; keto-reduction	Boceprevir	[284]
MR006806	Boceprevir	Boceprevir metabolite M31	Multi-steps Reaction - Oxidationn; keto-reduction	Boceprevir	[284]
MR000420	BPI-2009	BPI-2009 metabolite M4	Oxidation - Oxidation	BPI-2009	[209]
MR007349	BRN-0456976 M2	BRN-0456976 M1	Oxidation - N-dealkylation	BRN-0456976	[285]
MR000458	Bromfenac indolinone	Bromfenac metabolite M3	Unclear - Unclear	Bromfenac	[286], [287]
MR000491	Bupivacaine hydrochloride	Hydroxybuprenorphine	Oxidation - Hydroxylation	Buprenorphine hydrochloride	[288]
MR000490	Buprenorphine hydrochloride	Norbuprenorphine	Oxidation - N-Dealkylation	Buprenorphine hydrochloride	[288]
MR000524	Buspirone	Buspirone N-oxide	Oxidation - N-Oxidation	Buspirone	[289]
MR002575	Cabazitaxel	RPR123142	Oxidation - 10-O-Demethylation	Cabazitaxel	[290]
MR002576	Cabazitaxel	RPR112698	Oxidation - 7-O-Demethylation	Cabazitaxel	[290]
MR002577	Cabazitaxel	Cabazitaxel metabolite M1	Oxidation - Hydroxylation	Cabazitaxel	[290]
MR002586	3-hydroxycarbamazepine	2,3-Dihydroxycarbamazepine	Unclear - Unclear	Carbamazepine	[291]
MR002588	Carbamazepine	10,11-Epoxycarbamazepine	Oxidation - 10,11-Epoxidation	Carbamazepine	[291]
MR006088	CB-3304	Hydroxylated metabolite	Oxidation - Hydrolyzationn	CB-3304	[251]
MR006089	CB-3304	Hydroxylated metabolite	Oxidation - Hydrolyzationn	CB-3304	[251]
MR006092	CB-3304	CB-3304 Metabolite X	Oxidation - Bis-demethylation	CB-3304	[251]
MR007386	CBL-0102	CBL-0102 M2	Oxidation - N-desethylation	CBL-0102	[237]
MR007386	CBL-0102	CBL-0102 M2	Oxidation - O-demethylation	CBL-0102	[237]
MR013351	O-demethylated tetrandrine	Quinone methide	Unclear - Unclear	CBT-1	[263]
MR013352	Quinone methide	O-demethylated tetrandrine GSH conjugate	Unclear - Unclear	CBT-1	[263]
MR006095	CC-223	O-desmethyl CC-223	Oxidation - N-demethylation	CC-223	[252]
MR006096	CC-223	Keto CC-223	Unclear - Unclear	CC-223	[252]
MR006097	CC-223	N-oxide CC-223	Oxidation - N-oxidation	CC-223	[252]
MR006098	CC-223	Imine CC-223	Unclear - Unclear	CC-223	[252]
MR002541	Chenodeoxycholic acid	7alpha-hydroxy-3-oxo-5beta-cholan-24-oic Acid	Oxidation - Oxidation	Chenodeoxycholic acid	[292]
MR002542	Chenodeoxycholic acid	Gamma-muricholic acid	Unclear - Unclear	Chenodeoxycholic acid	[292]
MR000628	Chloroquine	(R)-chloroquine, N-desethyl	Oxidation - N-Dealkylation	Chloroquine	[293], [171], [170]
MR014160	Ciclosporin	AM1	Oxidation - Oxidation	Ciclosporin	[294]
MR014166	Ciclosporin	AM4N	Oxidation - Oxidation	Ciclosporin	[294]
MR000658	Cilostazol	OPC-13213	Unclear - Unclear	Cilostazol	[295], [296]
MR005295	Cis-4-hydroxytamoxifen	Endoxifen	Oxidation - N-demethylation	Cis-4-hydroxytamoxifen	[270]
MR005924	CJ-11974	M16 CL12764	Unclear - Unclear	CJ-11974	[297]
MR005935	CJ-11974	M17 CJ-12458	Unclear - Unclear	CJ-11974	[297]
MR006539	Clindamycin	Clindamycin sulfoxide	Unclear - Unclear	Clindamycin	[151]
MR006559	Clofazimine	Hydrolytic-deaminated clofazimine	Hydrolysis - Hydrolytic Deamination	Clofazimine	[106]
MR008660	(E)-4-OH-CLOM	(E)-4-OH-DE-CLOM	Unclear - Unclear	Clomiphene citrate	[46]
MR008656	Clomiphene citrate	(E)-DE-CLOM	Unclear - Unclear	Clomiphene citrate	[46]
MR008664	Clomiphene citrate	(Z)-DE-CLOM	Unclear - Unclear	Clomiphene citrate	[46]
MR006581	Clonazepam	7-amino-clonazepam	Reduction - Reduction	Clonazepam	[127]
MR006587	Clonidine	4-Hydroxyclonidine	Oxidation - 4-hydroxylation	Clonidine	[107]
MR006591	Clopidogrel bisulfate	2-Oxoclopidogrel	Oxidation - Oxidationn	Clopidogrel bisulfate	[19]
MR008451	DA-1229	4S-Hydroxyevogliptin	Oxidation - Hydroxylation	DA-1229	[262]
MR008454	DA-1229	4R-Hydroxyevogliptin	Oxidation - Hydroxylation	DA-1229	[262]
MR006516	DA-8159	N-desalkyludenafil	Oxidation - N-dealkylation	DA-8159	[164]
MR013673	Deoxycholic acid	1beta-OH-DCA	Unclear - Unclear	Deoxycholic acid	[47]
MR000819	Diazepam	Nordazepam	Oxidation - N-Demethylation	Diazepam	[298], [299], [300]
MR000825	Nordazepam	Oxazepam	Unclear - Unclear	Diazepam	[298], [299], [300]
MR000823	Temazepam	Oxazepam	Oxidation - N-Demethylation	Diazepam	[301], [300]
MR000883	Diethyldithiocarbamic acid methyl ester	.	Oxidation - Thiono-Oxidation	Disulfiram	[37]
MR000883	Diethyldithiocarbamic acid methyl ester	.	Oxidation - Sulfoxidation	Disulfiram	[37]
MR000891	Docetaxel	.	Unclear - Unclear	Docetaxel	[302]
MR006637	Doravirine	Doravirine M9 Metabolite	Oxidation - Oxidationn	Doravirine	[303]
MR005762	Doxapram hydrochloride	AHR 5955	Oxidation - Oxidationn	Doxapram hydrochloride	[304], [305], [108]
MR005766	Doxapram metabolite D	Doxapram metabolite C	Oxidation - Deethylation	Doxapram hydrochloride	[304], [305], [108]
MR006701	Dronedarone hydrochloride	N-debutyl-dronedarone	Oxidation - N-debutylation	Dronedarone hydrochloride	[306]
MR005771	Dutasteride	4'-hydroxydutasteride	Oxidation - Hydrolyzationn	Dutasteride	[307]
MR005772	Dutasteride	6beta-hydroxydutasteride	Oxidation - Hydrolyzationn	Dutasteride	[307]
MR005773	Dutasteride	1,2-dihydrodutasteride	Oxidation - Hydrolyzationn	Dutasteride	[307]
MR013315	E-3A	4-hydroxyestrone	Oxidation - 4-hydroxylation	E-3A	[308]
MR013470	EBP-994	EBP-994 M1	Unclear - Unclear	EBP-994	[179]
MR013471	EBP-994	EBP-994 M2	Unclear - Unclear	EBP-994	[179]
MR003447	Edoxaban	Edoxaban metabolite M7	Unclear - Unclear	Edoxaban	[309]
MR003449	Edoxaban	Edoxaban metabolite M6	Unclear - Unclear	Edoxaban	[309]
MR003450	Edoxaban	Edoxaban metabolite M5	Unclear - Unclear	Edoxaban	[309]
MR009039	EPIANDROSTERONE	EPIANDROSTERONE Metabolite M3	Unclear - Unclear	EPIANDROSTERONE	[310]
MR000910	Eplerenone	21-hydroxyeplerenone	Oxidation - Hydroxylation	Eplerenone	[153]
MR003018	Erlotinib hydrochloride	Erlotinib M14	Oxidation - O-demethylation	Erlotinib hydrochloride	[199], [5]
MR003007	Erlotinib M2	Erlotinib M14	Oxidation - O-demethylation	Erlotinib hydrochloride	[199], [5]
MR000932	Ertugliflozin	Ertugliflozin metabolite M2	Conjugation - Glucuronidation	Ertugliflozin	[311], [312]
MR000933	Ertugliflozin	Ertugliflozin metabolite M1a	Oxidation - Hydroxylation	Ertugliflozin	[311], [312]
MR000934	Ertugliflozin	Ertugliflozin metabolite M1b	Oxidation - Hydroxylation	Ertugliflozin	[311], [312]
MR000935	Ertugliflozin	Ertugliflozin metabolite M3	Conjugation - Glucuronidation	Ertugliflozin	[311], [312]
MR002627	Estradiol	4-hydroxyestrone	Oxidation - 4-Hydroxylation	Estradiol acetate	[313]
MR002650	Estradiol	4-hydroxyestrone	Oxidation - 4-Hydroxylation	Estradiol cypionate	[313]
MR002673	Estradiol	4-hydroxyestrone	Oxidation - 4-Hydroxylation	Estradiol valerate	[313]
MR002696	Estrone	2-hydroxyestrone	Oxidation - Hydroxylation	Estrone	[314]
MR002701	Estrone	4-OH-estrone	Oxidation - Hydroxylation	Estrone	[199]
MR002706	Estrone	16alpha-OH-estrone	Oxidation - Hydroxylation	Estrone	[199]
MR002702	Estrone	6alpha-OH-estrone	Oxidation - Hydroxylation	Estrone	[199]
MR002707	Estrone	16beta-OH-estrone	Oxidation - Hydroxylation	Estrone	[199]
MR002703	Estrone	6beta-estrone	Unclear - Unclear	Estrone	[199]
MR014077	Ethinylestradiol propanesulfonate	Unclear	Oxidation - 16alpha-hydroxylation	Ethinylestradiol propanesulfonate	[194], [195]
MR000982	Etoposide	Etoposide catechol	Unclear - Unclear	Etoposide	[315]
MR012196	Fenfluramine	Norfenfluramine	Unclear - Unclear	Fenfluramine	[316]
MR001023	Fentanyl citrate	Norfentanyl	Oxidation - N-Dealkylation	Fentanyl citrate	[109], [317], [318], [319]
MR005476	Fexinidazole	Fexinidazole sulfoxide metabolite (M1)	Oxidation - Oxidationn	Fexinidazole	[229], [230]
MR005477	Fexinidazole sulfoxide metabolite (M1)	Fexinidazole sulfone metabolite (M2)	Oxidation - Oxidationn	Fexinidazole	[229], [230]
MR001038	Finasteride	.	Unclear - Unclear	Finasteride	[302]
MR005012	Fluoxetine hydrochloride	Norfluoxetine	Oxidation - N-demethylation	Fluoxetine hydrochloride	[137], [19], [87], [320]
MR005057	Fluticasone propionate	Fluticasone 17beta-carboxylic acid	Unclear - Unclear	Fluticasone propionate	[321]
MR011675	Ganaxolone	16-OH ganazolone	Oxidation - Hydroxylation	Ganaxolone	[322]
MR001115	Gefitinib	Metabolism of the N-propoxymorpholino-group	Unclear - Unclear	Gefitinib	[323]
MR001117	Gefitinib	Oxidative defluorination of the halogenated phenyl group	Oxidation - Oxidative Defluorination	Gefitinib	[323]
MR007218	Glibenclamide	2-trans-hydroxycyclohexyl glyburide	Oxidation - Aliphatic hydroxylation	Glibenclamide	[324], [196]
MR007219	Glibenclamide	4-cis-hydroxycyclohexyl glyburide	Oxidation - Aliphatic hydroxylation	Glibenclamide	[324], [196]
MR007220	Glibenclamide	3-trans-Hydroxycyclohexyl glyburide	Oxidation - Aliphatic hydroxylation	Glibenclamide	[324], [196]
MR007221	Glibenclamide	Ethylhydroxycyclohexyl glyburide	Oxidation - Aliphatic hydroxylation	Glibenclamide	[324], [196]
MR007219	Glibenclamide	4-trans-hydroxycyclohexyl glyburide	Oxidation - Aliphatic hydroxylation	Glibenclamide	[324], [196], [325]
MR007222	Glibenclamide	3-cis-Hydroxycyclohexyl glyburide	Oxidation - Aliphatic hydroxylation	Glibenclamide	[324], [196], [325]
MR003919	H3B-6527	H3B-68730	Oxidation - N-deethylation	H3B-6527	[264]
MR005071	Halofantrine	N-debutylhalofantrine	Oxidation - N-debutylation	Halofantrine	[176]
MR006056	Fexinidazole Sulfone M1	Fexinidazole Sulfone M2	Oxidation - Oxidationn	HOE-239	[229]
MR006055	HOE-239	Fexinidazole Sulfone M1	Oxidation - Oxidationn	HOE-239	[229]
MR012185	Hydroxychloroquine	Monodesethylchloroquine	Unclear - Unclear	Hydroxychloroquine	[326], [171]
MR005144	Hydroxyzine	Cetirizine	Oxidation - Oxidationn	Hydroxyzine	[327], [328]
MR012963	Ibrutinib	PCI-45227 (M37)	Multi-steps Reaction - Epoxidation; hydrolyzation	Ibrutinib	[17]
MR004650	Ifosfamide	4-Hydroxyifosfamide	Oxidation - 4-hydroxylation	Ifosfamide	[329]
MR004662	Ifosfamide	3-Dechloroethylifosfamide	Unclear - Unclear	Ifosfamide	[137], [329]
MR004663	Ifosfamide	Dechloroethylifosfamide	Unclear - Unclear	Ifosfamide	[329]
MR004660	Ifosfamide	Chloroacetaldehyde	Unclear - Unclear	Ifosfamide	[329], [330]
MR012007	Imatinib	N-desmethyl-imatinib	Unclear - Unclear	Imatinib	[331]
MR004669	Imatinib mesylate	N-Desmethylimatinib	Oxidation - N-demethylation	Imatinib mesylate	[19], [332], [333]
MR004625	Imipramine	Desipramine	Unclear - Unclear	Imipramine oxide	[334], [335]
MR011238	Indiplon	N-desmethylIndiplon	Oxidation - N-demethylation	indiplon	[336]
MR009235	Ingrezza	NBI-136110	Oxidation - Oxidation	Ingrezza	[201], [337]
MR001224	Irinotecan hydrochloride	7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino] carbonyloxycamptothecin	Unclear - Unclear	Irinotecan hydrochloride	[338], [339]
MR002854	Isavuconazole	.	Unclear - Unclear	Isavuconazole	[340], [341]
MR002794	Isavuconazole	.	Unclear - Unclear	Isavuconazonium	[341]
MR001276	Istradefylline	1-beta-hydroxylated Istradefylline	Oxidation - Hydroxylation	Istradefylline	[89]
MR002855	Ivacaftor	M1 (hydroxymethyl-ivacaftor)	Oxidation - Hydroxylation	Ivacaftor	[342], [156]
MR003687	KW-5338	KW-5338 Metabolite M1	Oxidation - Hydrolyzationn	KW-5338	[343]
MR003688	KW-5338	KW-5338 Metabolite M3	Oxidation - Hydrolyzationn	KW-5338	[343]
MR003689	KW-5338	KW-5338 Metabolite M4	Oxidation - Hydrolyzationn	KW-5338	[343]
MR003691	KW-5338	KW-5338 Metabolite M2	Oxidation - Hydrolyzationn	KW-5338	[343]
MR003686	KW-5338	5-hydroxydomperidone	Unclear - Unclear	KW-5338	[344]
MR001413	Lansoprazole	5-hydroxylansoprazole	Oxidation - Hydroxylation	Lansoprazole	[345], [346]
MR001429	Lapatinib ditosylate	N-hydroxy lapatinib	Oxidation - N-Hydroxylation	Lapatinib ditosylate	[347]
MR008875	Lasofoxifene	5-hydroxy-lasofoxifene (5-OHLAS)	Oxidation - 5-hydroxylation	Lasofoxifene	[69]
MR008874	Lasofoxifene	7-hydroxy-lasofoxifene (7-OHLAS)	Oxidation - 7-hydroxylation	Lasofoxifene	[69]
MR003708	LAU-7b	4'-hydroxy 4-HPR	Unclear - Unclear	LAU-7b	[348]
MR010933	Lenvatinib	O-demethyl Lenvatinib	Unclear - Unclear	Lenvatinib	[134]
MR010934	Lenvatinib	N-descyclopropyl lenvatinib	Unclear - Unclear	Lenvatinib	[134]
MR001444	Letermovir	.	Unclear - Unclear	Letermovir	[91]
MR003114	Levomethadyl acetate hydrochloride	.	Unclear - Unclear	Levomethadyl acetate hydrochloride	[302]
MR001514	Levonorgestrel	.	Unclear - Unclear	Levonorgestrel	[349]
MR006058	Lilly-112531	Vindesine N-oxide	Oxidation - N-oxidation	Lilly-112531	[350]
MR005524	Lonafarnib	Lonafarnib metabolite M1	Oxidation - Oxidationn	Lonafarnib	[179], [351]
MR005525	Lonafarnib metabolite M1	Lonafarnib metabolite M2	Other reaction - Dehydration	Lonafarnib	[179], [351]
MR006912	Lorlatinib	Lorlatinib benzoic acid metabolite (M8)	Oxidation - Oxidationn cleavage	Lorlatinib	[352]
MR006916	Losartan potassium	Losartan carboxylic acid	Oxidation - N-oxidation	Losartan potassium	[353]
MR006922	beta-hydroxy acid of lovastatin	6'-beta-Hydroxylovastatin	Oxidation - Hydrolyzationn	Lovastatin	[135]
MR006925	Loxapine succinate	Loxapine N-oxide	Oxidation - Oxidationn	Loxapine succinate	[110]
MR007964	Loxoprofen gel	Loxoprofen gel metabolite M3	Unclear - Unclear	Loxoprofen gel	[354], [18]
MR012006	Minium ion intermediate	MCN538	Unclear - Unclear	Masitinib	[355]
MR010182	Mavacamten	MYK-1078	Unclear - Unclear	Mavacamten	[356]
MR010178	Mavacamten	MYK-2241	Unclear - Unclear	Mavacamten	[356]
MR001636	Megestrol acetate	Megestrol acetate metabolite M1	Oxidation - Oxidation	Megestrol acetate	[357]
MR001645	17alpha-Ethinylestradiol	2-hydroxyethinylestradiol	Oxidation - 2-Hydroxylation	Mestranol	[194], [195]
MR001646	17alpha-Ethinylestradiol	4-hydroxyethinylestradiol	Oxidation - 4-Hydroxylation	Mestranol	[194], [195]
MR001647	17alpha-Ethinylestradiol	6-hydroxyethinylestradiol	Oxidation - 6-Hydroxylation	Mestranol	[194], [195]
MR001648	17alpha-Ethinylestradiol	7-hydroxyethinylestradiol	Oxidation - 7-Hydroxylation	Mestranol	[194], [195]
MR001649	17alpha-Ethinylestradiol	16alpha-hydroxyethinylestradiol	Oxidation - 16-Hydroxylation	Mestranol	[194], [195]
MR009998	Methadone	EDDP	Oxidation - N-demethylation	Methadone	[136], [358]
MR004727	Metronidazole	2-hydroxymetronidazole	Oxidation - Hydrolyzationn	Metronidazole	[25], [359], [360], [361]
MR012692	MKC-442	BIU	Unclear - Unclear	MKC-442	[243]
MR011622	MLN4924	MLN4924 Metabolite M1	Oxidation - Hydroxylation	MLN4924	[212]
MR011624	MLN4924	MLN4924 Metabolite M3	Oxidation - Hydroxylation	MLN4924	[212]
MR004802	Montelukast sodium	25-OH Montelukast	Unclear - Unclear	Montelukast sodium	[20]
MR004799	Montelukast sodium	Montelukast sulfoxide	Oxidation - S-oxidation	Montelukast sodium	[19], [20]
MR004800	Montelukast sodium	Montelukast metabolite M5a	Oxidation - Hydrolyzationn	Montelukast sodium	[19], [20]
MR004801	Montelukast sodium	Montelukast metabolite M5b	Oxidation - Hydrolyzationn	Montelukast sodium	[19], [20]
MR004812	Mycophenolic acid	6-O-desmethyl-MPA (DM-MPA)	Unclear - Unclear	Mycophenolate mofetil	[362]
MR004823	Mycophenolic acid	6-O-desmethyl-mycophenolic acid	Oxidation - Demethylation	Mycophenolic acid	[137], [138]
MR003386	S-Naftopidil	R-Naftopidil metabolite M2	Unclear - Unclear	Naftopidil	[363], [364]
MR003387	S-Naftopidil	R-Naftopidil metabolite M3	Unclear - Unclear	Naftopidil	[363], [364]
MR010771	Nalmefene	Nornalmefene	Oxidation - Dealkylation	Nalmefene	[365]
MR003787	NE-10064	NE-10064 Metabolite M5	Unclear - Unclear	NE-10064	[210]
MR003783	NE-10064	NE-10064 Metabolite M4	Oxidation - N-oxidation	NE-10064	[210]
MR003269	Nevirapine	12-hydroxynevirapine	Oxidation - Hydroxylation	Nevirapine	[366], [367], [368]
MR003270	Nevirapine	2-hydroxynevirapine	Oxidation - 2-Hydroxylation	Nevirapine	[366], [367]
MR001730	Nicardipine hydrochloride	Dehydronicardipine	Oxidation - Heteroring Dehydrogenation	Nicardipine hydrochloride	[369], [63], [370]
MR001736	2,6-dimethyl-4-(2-nitrophenyl)-5-methoxycarbonyl-pyridine-3-carboxylic acid	2-hydroxymethyl-pyridine carboxylic acid	Unclear - Unclear	Nifedipine	[371]
MR001737	Nifedipine	2,6-dimethyl-4-(2-nitrophenyl)-5-methoxycarbonyl-pyridine-3-carboxylic acid	Unclear - Unclear	Nifedipine	[372]
MR003531	Nintedanib esylate	Nintedanib metabolite M6	Oxidation - Demethylation	Nintedanib esylate	[373]
MR001764	Nitrofurantoin	Nitrofurantoin metabolite M10	Oxidation - Oxidation	Nitrofurantoin	[374]
MR001765	Nitrofurantoin	Nitrofurantoin metabolite 8(M1/M2)	Oxidation - Oxidation	Nitrofurantoin	[374]
MR001766	Nitrofurantoin	Nitrofurantoin metabolite 9(M1/M2)	Oxidation - Oxidation	Nitrofurantoin	[374]
MR001762	Nitrofurantoin metabolite M10	Nitrofurantoin metabolite 8(M1/M2)	Oxidation - Oxidation	Nitrofurantoin	[374]
MR001763	Nitrofurantoin metabolite M10	Nitrofurantoin metabolite 9(M1/M2)	Oxidation - Oxidation	Nitrofurantoin	[374]
MR006380	NSC-122758	4-Hydroxyretinoic acid	Oxidation - 4-hydroxylation	NSC-122758	[35]
MR006381	NSC-122758	All-trans-18-Hydroxyretinoic acid	Oxidation - Hydrolyzationn	NSC-122758	[35], [211]
MR006382	NSC-122758	5,6-Epoxyretinoic acid	Unclear - Unclear	NSC-122758	[35]
MR013882	Nuplazid	AC-279	Unclear - Unclear	Nuplazid	[244]
MR001812	Olaparib metabolite M10	Olaparib metabolite M12	Oxidation - Alcohol Oxidation	Olaparib	[375]
MR001877	Oxybutynin chloride	N-desethyloxybutynin	Oxidation - N-Deethylation	Oxybutynin chloride	[376], [182]
MR001878	Noroxycodone	Noroxymorphone	Oxidation - N-Demethylation	Oxycodone hydrochloride	[39], [377]
MR001881	Oxycodone hydrochloride	Noroxycodone	Oxidation - N-Demethylation	Oxycodone hydrochloride	[39], [377], [378]
MR001886	Oxymorphone	Noroxymorphone	Oxidation - N-Demethylation	Oxycodone hydrochloride	[379]
MR005572	RP101075	RP112289	Unclear - Unclear	Ozanimod	[13]
MR005572	RP101075	RP112289	Unclear - Unclear	Ozanimod	[13]
MR014024	RP101075	RP112289	Unclear	Ozanimod	[13]
MR001924	Paliperidone	9-hydroxyrisperidone	Unclear - Unclear	Paliperidone	[161]
MR001925	Paliperidone	Risperidone	Oxidation - Dehydrogenation	Paliperidone	[380]
MR002864	Palonosetron hydrochloride	Palonosetron metabolite M4	Oxidation - Hydroxylation	Palonosetron hydrochloride	[141]
MR002865	Palonosetron hydrochloride	Palonosetron metabolite M9	Oxidation - N-Oxidation	Palonosetron hydrochloride	[141]
MR003337	Paroxetine hydrochloride	Paroxetine catechol	Unclear - Unclear	Paroxetine hydrochloride	[19], [381]
MR001972	Pentamidine isethionate	Pentamidine Amidoxime	Oxidation - N-Hydroxylation	Pentamidine isethionate	[162], [382]
MR013146	Pexacerfont	DPH-124921	Unclear - Unclear	Pexacerfont	[227]
MR013148	Pexacerfont	DPH-123554	Unclear - Unclear	Pexacerfont	[227]
MR013150	Pexacerfont	Pexacerfont Metabolite M8	Unclear - Unclear	Pexacerfont	[227]
MR013153	Pexacerfont	BMS-749241	Unclear - Unclear	Pexacerfont	[227]
MR011750	PF-06463922	PF-06895751 (M8)	Unclear - Unclear	PF-06463922	[235]
MR002018	Phenelzine	Phenethylamine	Hydrolysis - Hydrolysis	Phenelzine	[383]
MR002023	Phenobarbital	4-hydroxyphenobarbital	Oxidation - 4-Hydroxylation	Phenobarbital	[19]
MR002024	Phenobarbital	Mephobarbital	Conjugation - Methylation	Phenobarbital	[384]
MR002030	Hydroxyphenytoin	Phenytoin catechol	Oxidation - Oxidation	Phenytoin	[137]
MR013198	Ponesimod	Ponesimod M12 Metabolite (ACT-204426)	Oxidation - Oxidationn	Ponesimod	[52]
MR013759	PPI-2458	PPI-2458 metabolite M1	Oxidation - Hydroxylation	PPI-2458	[258]
MR013760	PPI-2458	PPI-2458 metabolite M2	Unclear - Unclear	PPI-2458	[258]
MR013761	PPI-2458	PPI-2458 metabolite M3	Unclear - Unclear	PPI-2458	[258]
MR013762	PPI-2458	PPI-2458 metabolite M4	Oxidation - Hydroxylation	PPI-2458	[258]
MR013763	PPI-2458	PPI-2458 metabolite M5	Unclear - Unclear	PPI-2458	[258]
MR013764	PPI-2458	PPI-2458 metabolite M6	Unclear - Unclear	PPI-2458	[258]
MR002166	Prochlorperazine	N-demethylation	Oxidation - N-Demethylation	Prochlorperazine	[118], [385], [386]
MR002167	Prochlorperazine	Prochlorperazine sulfoxide	Oxidation - Sulfoxidation	Prochlorperazine	[118], [385], [386]
MR002168	Prochlorperazine	Prochlorperazine 7-hydroxide	Oxidation - 7-Hydroxylation	Prochlorperazine	[118], [385], [386]
MR002204	Quetiapine fumarate	7-hydroxyquetiapine	Oxidation - Hydroxylation	Quetiapine fumarate	[387], [388]
MR002203	Quetiapine fumarate	N-desalkylquetiapine	Unclear - Unclear	Quetiapine fumarate	[387], [388]
MR002205	Quetiapine fumarate	Quetiapine sulfoxide	Oxidation - Sulfoxidation	Quetiapine fumarate	[387]
MR002206	Quetiapine fumarate	O-desalkylquetiapine	Oxidation - N-Dealkylation	Quetiapine fumarate	[387]
MR009532	Rilpivirine hydrochloride	Rilpivirine M2	Oxidation - Hydroxylation	Rilpivirine hydrochloride	[94]
MR009534	Rilpivirine hydrochloride	Rilpivirine M4	Oxidation - Hydroxylation	Rilpivirine hydrochloride	[94]
MR009536	Rilpivirine hydrochloride	Rilpivirine M1	Oxidation - Hydroxylation	Rilpivirine hydrochloride	[94]
MR009537	Rilpivirine hydrochloride	Rilpivirine M3	Oxidation - Hydroxylation	Rilpivirine hydrochloride	[94]
MR009550	Ritonavir	N-Desmethylritonavir	Oxidation - N-demethylation	Ritonavir	[19]
MR009550	Ritonavir	Hydroxy Ritonavir	Other reaction - Hydoxylation	Ritonavir	[19]
MR009551	Ritonavir	Ritonavir metabolite M1	Unclear - Unclear	Ritonavir	[19]
MR009552	Ritonavir	Ritonavir metabolite M11	Unclear - Unclear	Ritonavir	[19]
MR006437	RO-7-0207	(2S,3S,4S,5R)-6-[1-chloro-3-(2-methyl-5-nitroimidazol-1-yl)propan-2-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid	Unclear - Unclear	RO-7-0207	[224]
MR006596	Romidepsin	Romidepsin metabolite M1	Reduction - Reduction	Romidepsin	[389]
MR002221	Salmeterol xinafoate	Alpha-hydroxysalmeterol	Oxidation - Hydroxylation	Salmeterol xinafoate	[390], [391], [392]
MR002885	Saquinavir mesylate	M2 di-hydroxylated metabolite	Oxidation - Hydroxylation	Saquinavir mesylate	[393], [120], [394]
MR002223	Saxagliptin hydrochloride	5-hydroxy saxagliptin	Oxidation - Hydroxylation	Saxagliptin hydrochloride	[187]
MR006458	SCH-417690	O-Desmethylvicriviroc	Oxidation - O-demethylation	SCH-417690	[19]
MR006460	SCH-417690	Vicriviroc N-oxide	Oxidation - N-oxidation	SCH-417690	[19]
MR006461	SCH-417690	N-Desalkylvicriviroc	Unclear - Unclear	SCH-417690	[19]
MR006462	SCH-417690	N,N-Desalkylvicriviroc	Unclear - Unclear	SCH-417690	[19]
MR002224	Secnidazole	Hydroxymethyl metabolite of secnidazole	Oxidation - Oxidation	Secnidazole	[163], [395]
MR013895	Sildenafil	N-desmethyl Sildenafil	Unclear - Unclear	Sildenafil	[396], [397], [188]
MR002252	Sildenafil citrate	Desmethylsildenafil	Oxidation - N-Demethylation	Sildenafil citrate	[164], [398], [399]
MR002253	Sildenafil citrate	N-dealkyl Sildenafil	Oxidation - N-Dealkylation	Sildenafil citrate	[19]
MR013434	Simvastatin	6'-beta-Hydroxysimvastatin	Oxidation - Aliphatic hydroxylation	Simvastatin	[369]
MR013435	Simvastatin	Pravastatin 3,5-dihydrodiol	Oxidation - Aliphatic hydroxylation	Simvastatin	[369]
MR013436	Simvastatin	6-Exomethylenesimvastatin	Oxidation - Dehydrogenation	Simvastatin	[400]
MR006834	Sorafenib	Pyridine N-oxide glucuronide	Multi-steps Reaction - Oxidationn; glucuronidation	Sorafenib	[137], [401]
MR006833	Sorafenib	Pyridostigmine	Oxidation - Oxidationn	Sorafenib	[137]
MR008425	STX 64	STX 64 metabolite M13	Oxidation - Hydroxylation	STX 64	[254]
MR008436	STX 64	STX 64 metabolite M14	Oxidation - Hydroxylation	STX 64	[254]
MR002324	Tacrolimus	31-O-Demethyltacrolimus	Oxidation - Deamination	Tacrolimus	[402]
MR002325	Tacrolimus	13-O-Desmethyltacrolimus	Oxidation - Deamination	Tacrolimus	[402]
MR002326	Tacrolimus	15-O-Desmethyltacrolimus	Oxidation - Deamination	Tacrolimus	[402]
MR002329	Tadalafil	Tadalafil catechol	Oxidation - Oxidation	Tadalafil	[403], [188]
MR012520	TAK-063	TAK-063 MI	Unclear - Unclear	TAK-063	[246]
MR011529	TAK-272	TAK-272 Metabolite M1	Unclear - Unclear	TAK-272	[247]
MR006472	TAK-875	TAK-875 Metabolite M-I	Unclear - Unclear	TAK-875	[214]
MR006475	TAK-875	Fasiglifam-G	Conjugation - Conjugation	TAK-875	[214]
MR003530	4-hydroxytamoxifen	Endoxifen	Conjugation - Sulfation	Tamoxifen citrate	[404]
MR003512	N,N-didesmethyltamoxifen	Tamoxifen metabolite Y	Unclear - Unclear	Tamoxifen citrate	[404]
MR003511	N-Desmethyltamoxifen	N,N-didesmethyltamoxifen	Unclear - Unclear	Tamoxifen citrate	[404]
MR003510	Tamoxifen citrate	N-Desmethyltamoxifen	Oxidation - N-Dealkylation	Tamoxifen citrate	[405], [406], [407], [408], [409]
MR003513	Tamoxifen metabolite Y	Tamoxifen metabolite E	Oxidation - Ether Cleavage	Tamoxifen citrate	[404]
MR005270	5'-hydroxytegafur	Fluorouracil	Other reaction - Degradation	Tegafur	[63], [204]
MR011787	Monodemethylated telapristone	Didemethylated telapristone	Oxidation - Demethylation	Telapristone	[240]
MR011786	Telapristone	Monodemethylated telapristone	Oxidation - Demethylation	Telapristone	[240]
MR011788	Telapristone	17alpha-Hydroxy telapristone	Oxidation - Hydroxylation	Telapristone	[240]
MR002376	O-conjugate of temazepam	Temazepam metabolite M1	Oxidation - Demethylation	Temazepam	[410], [411]
MR002378	Temazepam	Oxazepam	Oxidation - Demethylation	Temazepam	[412], [410]
MR002385	Temsirolimus	27-O-desmethyl temsirolimus	Oxidation - O-Demethylation	Temsirolimus	[413]
MR002386	Temsirolimus	25-hydroxy temsirolimus	Oxidation - Hydroxylation	Temsirolimus	[413]
MR002387	Temsirolimus	Hydroxy-piperidine temsirolimus	Oxidation - Hydroxylation	Temsirolimus	[413]
MR002391	Tenapanor	Tenapanor metabolite M1	Unclear - Unclear	Tenapanor	[414]
MR002393	Teniposide	Teniposide catechol derivative	Oxidation - O-Demethylation	Teniposide	[415]
MR002393	Teniposide	Teniposide catechol	Unclear - Unclear	Teniposide	[416]
MR002397	Teniposide	O-demethylated Teniposide	Unclear - Unclear	Teniposide	[416]
MR004973	Ticagrelor	AR-C124910XX	Unclear - Unclear	Ticagrelor	[56], [57]
MR011610	Tivantinib	Tivantinib Metabolite M10	Oxidation - Oxidation	Tivantinib	[208]
MR011603	Tivantinib	Tivantinib Metabolite M4	Unclear - Unclear	Tivantinib	[208]
MR011606	Tivantinib Metabolite M4	Tivantinib Metabolite M11	Oxidation - Oxidation	Tivantinib	[208]
MR011609	Tivantinib Metabolite M5	Tivantinib Metabolite M12	Oxidation - Oxidation	Tivantinib	[208]
MR011602	Tivantinib Metabolite M8	Tivantinib Metabolite M9	Oxidation - Oxidation	Tivantinib	[208]
MR006149	TMC-120	Unclear	Unclear - Unclear	TMC-120	[417]
MR009636	Tretinoin	18-OH-RA	Oxidation - Hydroxylation	Tretinoin	[35], [418], [419]
MR009626	Tretinoin	4-Hydroxyretinoic acid	Oxidation - 4-hydroxylation	Tretinoin	[35], [419]
MR009629	Tretinoin	5,6-epoxy-RA	Oxidation - Ring epoxidation	Tretinoin	[418], [418], [35]
MR002449	Triamcinolone diacetate	6-beta-hydroxy-triamcinolone	Oxidation - 6-Beta-Hydroxylation	Triamcinolone diacetate	[420], [421], [190]
MR002460	Trimethoprim	Calpha-OH-TMP	Oxidation - C-Oxidation	Trimethoprim	[422]
MR008174	Tucatinib	Tucatinib metabolite M23	Oxidation - Oxidation	Tucatinib	[58]
MR002487	2-N-Propyl-4-oxopentanoic acid	2-Propylsuccinic acid	Oxidation - 5-Hydroxylation	Valproic acid	[19]
MR002492	Valproic acid	4-hydroxyvalproic acid	Oxidation - 4-Hydroxylation	Valproic acid	[19]
MR002494	Valproic acid	5-hydroxyvalproic acid	Oxidation - 5-Hydroxylation	Valproic acid	[19]
MR002495	Valproic acid	3-hydroxyvalproic acid	Unclear - Unclear	Valproic acid	[19]
MR002504	Vardenafil hydrochloride	N-desethyl vardenafil	Oxidation - N-Deethylation	Vardenafil hydrochloride	[423], [424], [164]
MR010528	D-617	D-620	Unclear - Unclear	Verapamil	[19]
MR010530	D-702	D-620	Unclear - Unclear	Verapamil	[19]
MR010523	Verapamil	Norverapamil	Unclear - Unclear	Verapamil	[19]
MR005651	O-Desmethylverapamil (D-702)	Verapamil metabolite D-620	Oxidation - N-dealkylation	Verapamil hydrochloride	[19]
MR005647	Verapamil hydrochloride	Norverapamil	Oxidation - N-demethylation	Verapamil hydrochloride	[19]
MR005646	Verapamil metabolite D-617	Verapamil metabolite D-620	Oxidation - N-dealkylation	Verapamil hydrochloride	[19]
MR005654	Vincristine sulfate	Vincristine metabolite M1	Oxidation - Oxidationn	Vincristine sulfate	[425]
MR005659	Vismodegib	Vismodegib metabolite M1	Unclear - Unclear	Vismodegib	[97], [98], [99]
MR013245	Voriconazole	Voriconazole N-Oxide Metabolite	Oxidation - Oxidationn	Voriconazole	[145], [146]
MR013250	Voriconazole	4-Hydroxyvoriconazole	Oxidation - Hydrolyzationn	Voriconazole	[145], [146]
MR005674	Vortioxetine hydrobromide	Vortioxetine Metabolite 4a	Oxidation - Oxidationn	Vortioxetine hydrobromide	[122], [426]
MR005675	Voxelotor	Unclear	Oxidation - Oxidationn	Voxelotor	[166]
MR006486	VX-661	Tezacaftor metabolite M1	Oxidation - Hydrolyzationn	VX-661	[427]
MR006487	VX-661	Tezacaftor metabolite M2	Oxidation - Hydrolyzationn	VX-661	[427]
MR006488	VX-661	Tezacaftor metabolite M5	Oxidation - Hydrolyzationn	VX-661	[427]
MR013081	Zotepine	Norzotepine	Oxidation - N-demethylation	Zotepine	[199], [428]
MR013084	Zotepine	3-OH-zotepine	Oxidation - Aromatic hydroxylation	Zotepine	[199]
MR013085	Zotepine	Zotepine S-oxide	Oxidation - S-oxidation	Zotepine	[199]


⏷ Show the Full List of 360 MR(s)

Tissue/Disease-Specific Protein Abundances of This DME
Tissue-specific Protein Abundances in Healthy Individuals		Click to Show/Hide

Download the Tissue-Specific Variation(s) Profile
ICD Disease Classification 01	Infectious/parasitic disease	Click to Show/Hide
ICD-11: 1C1H	Necrotising ulcerative gingivitis	Click to Show/Hide
The Studied Tissue	Gingival tissue
The Specified Disease	Bacterial infection of gingival [ICD-11:1C1H]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.41E-16; Fold-change: -1.05E+00; Z-score: -1.39E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 1E30	Influenza	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Influenza [ICD-11:1E30]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.55E-02; Fold-change: -8.41E-01; Z-score: -2.76E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 1E51	Chronic viral hepatitis	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Chronic hepatitis C [ICD-11:1E51.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 9.32E-01; Fold-change: 5.45E-02; Z-score: 3.88E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 1G41	Sepsis with septic shock	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Sepsis with septic shock [ICD-11:1G41]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.43E-02; Fold-change: 2.35E-02; Z-score: 1.49E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: CA40	Respiratory syncytial virus infection	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Pediatric respiratory syncytial virus infection [ICD-11:CA40.11]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 6.84E-02; Fold-change: -6.78E-02; Z-score: -6.30E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: CA42	Rhinovirus infection	Click to Show/Hide
The Studied Tissue	Nasal epithelium tissue
The Specified Disease	Rhinovirus infection [ICD-11:CA42.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.31E-01; Fold-change: -5.34E-02; Z-score: -1.02E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: KA60	Neonatal sepsis	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Neonatal sepsis [ICD-11:KA60]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.71E-01; Fold-change: -2.86E-02; Z-score: -1.76E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 02	Neoplasm	Click to Show/Hide
ICD-11: 2A00	Brain cancer	Click to Show/Hide
The Studied Tissue	Nervous tissue
The Specified Disease	Glioblastopma [ICD-11:2A00.00]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.80E-10; Fold-change: 1.27E-04; Z-score: 4.77E-04
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Brain stem tissue
The Specified Disease	Glioma [ICD-11:2A00.0Y-2A00.0Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 7.76E-01; Fold-change: -2.05E-01; Z-score: -5.72E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	White matter tissue
The Specified Disease	Glioma [ICD-11:2A00.0Y-2A00.0Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 9.78E-01; Fold-change: -1.22E-03; Z-score: -4.10E-03
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Brain stem tissue
The Specified Disease	Neuroectodermal tumour [ICD-11:2A00.11]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.16E-06; Fold-change: -7.41E-01; Z-score: -4.22E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 2A20	Myeloproliferative neoplasm	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Myelofibrosis [ICD-11:2A20.2]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 8.26E-04; Fold-change: 2.01E-01; Z-score: 1.65E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Whole blood
The Specified Disease	Polycythemia vera [ICD-11:2A20.4]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.11E-09; Fold-change: 1.32E-01; Z-score: 1.50E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 2A36	Myelodysplastic syndrome	Click to Show/Hide
The Studied Tissue	Bone marrow
The Specified Disease	Myelodysplastic syndrome [ICD-11:2A36-2A3Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 7.43E-01; Fold-change: -3.46E-02; Z-score: -2.62E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 7.33E-01; Fold-change: -2.12E-02; Z-score: -1.06E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2A81	Diffuse large B-cell lymphoma	Click to Show/Hide
The Studied Tissue	Tonsil tissue
The Specified Disease	Diffuse large B-cell lymphoma [ICD-11:2A81]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.42E-01; Fold-change: -8.12E-02; Z-score: -8.53E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 2A83	Plasma cell neoplasm	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Multiple myeloma [ICD-11:2A83.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.26E-02; Fold-change: 7.10E-02; Z-score: 1.00E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Bone marrow
The Specified Disease	Multiple myeloma [ICD-11:2A83.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 7.23E-01; Fold-change: -2.28E-02; Z-score: -3.11E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 2B33	Leukaemia	Click to Show/Hide
The Studied Tissue	Bone marrow
The Specified Disease	Acute myelocytic leukaemia [ICD-11:2B33.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.69E-01; Fold-change: 2.37E-02; Z-score: 2.14E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 2B6E	Oral cancer	Click to Show/Hide
The Studied Tissue	Oral tissue
The Specified Disease	Oral cancer [ICD-11:2B6E]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.58E-05; Fold-change: -1.72E+00; Z-score: -1.46E+00
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 1.15E-33; Fold-change: -3.05E+00; Z-score: -2.48E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2B70	Esophageal cancer	Click to Show/Hide
The Studied Tissue	Esophagus
The Specified Disease	Esophagal cancer [ICD-11:2B70]
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 1.02E-01; Fold-change: -4.60E-01; Z-score: -5.29E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
ICD-11: 2B72	Stomach cancer	Click to Show/Hide
The Studied Tissue	Gastric tissue
The Specified Disease	Gastric cancer [ICD-11:2B72]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.90E-01; Fold-change: -1.84E+00; Z-score: -6.76E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 1.04E-15; Fold-change: -2.33E+00; Z-score: -4.49E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2B90	Colon cancer	Click to Show/Hide
The Studied Tissue	Colon tissue
The Specified Disease	Colon cancer [ICD-11:2B90]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.36E-06; Fold-change: -3.51E-01; Z-score: -4.31E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 2.52E-03; Fold-change: -4.89E-01; Z-score: -3.72E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2B92	Rectal cancer	Click to Show/Hide
The Studied Tissue	Rectal colon tissue
The Specified Disease	Rectal cancer [ICD-11:2B92]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.78E-02; Fold-change: 4.07E-01; Z-score: 1.09E+00
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 5.93E-01; Fold-change: 1.71E-02; Z-score: 2.87E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2C10	Pancreatic cancer	Click to Show/Hide
The Studied Tissue	Pancreas
The Specified Disease	Pancreatic cancer [ICD-11:2C10]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.16E-03; Fold-change: 1.91E+00; Z-score: 1.07E+00
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 1.41E-05; Fold-change: 1.56E+00; Z-score: 7.61E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2C12	Liver cancer	Click to Show/Hide
The Studied Tissue	Liver tissue
The Specified Disease	Liver cancer [ICD-11:2C12.0]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.87E-05; Fold-change: -5.90E-01; Z-score: -7.24E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 3.03E-31; Fold-change: -8.97E-01; Z-score: -1.27E+00
The Expression Level of Disease Section Compare with the Other Disease Section	p-value: 8.83E-15; Fold-change: -1.43E+00; Z-score: -1.25E+01
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals DME expression in tissue other than the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual Download DME expression data in the tissue of the other disease section
ICD-11: 2C25	Lung cancer	Click to Show/Hide
The Studied Tissue	Lung tissue
The Specified Disease	Lung cancer [ICD-11:2C25]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.12E-38; Fold-change: -1.81E+00; Z-score: -2.01E+00
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 1.64E-34; Fold-change: -2.25E+00; Z-score: -2.29E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2C30	Skin cancer	Click to Show/Hide
The Studied Tissue	Skin
The Specified Disease	Melanoma [ICD-11:2C30]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.21E-03; Fold-change: -1.79E+00; Z-score: -1.23E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Skin
The Specified Disease	Skin cancer [ICD-11:2C30-2C3Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.44E-89; Fold-change: -2.17E+00; Z-score: -2.38E+00
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 1.35E-154; Fold-change: -3.13E+00; Z-score: -4.95E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2C6Z	Breast cancer	Click to Show/Hide
The Studied Tissue	Breast tissue
The Specified Disease	Breast cancer [ICD-11:2C60-2C6Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.56E-19; Fold-change: -3.06E-01; Z-score: -6.18E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 1.60E-03; Fold-change: -2.05E-01; Z-score: -4.67E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2C73	Ovarian cancer	Click to Show/Hide
The Studied Tissue	Ovarian tissue
The Specified Disease	Ovarian cancer [ICD-11:2C73]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 6.08E-01; Fold-change: 2.08E-01; Z-score: 1.69E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 2.65E-01; Fold-change: -1.36E+00; Z-score: -7.91E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2C77	Cervical cancer	Click to Show/Hide
The Studied Tissue	Cervical tissue
The Specified Disease	Cervical cancer [ICD-11:2C77]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.22E-09; Fold-change: -1.13E+00; Z-score: -1.72E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 2C78	Uterine cancer	Click to Show/Hide
The Studied Tissue	Endometrium tissue
The Specified Disease	Uterine cancer [ICD-11:2C78]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.32E-01; Fold-change: 2.09E-01; Z-score: 1.24E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 9.22E-02; Fold-change: -1.79E-01; Z-score: -5.71E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2C82	Prostate cancer	Click to Show/Hide
The Studied Tissue	Prostate
The Specified Disease	Prostate cancer [ICD-11:2C82]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.69E-06; Fold-change: -1.53E+00; Z-score: -1.39E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 2C90	Renal cancer	Click to Show/Hide
The Studied Tissue	Kidney
The Specified Disease	Renal cancer [ICD-11:2C90-2C91]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.51E-02; Fold-change: 1.53E+00; Z-score: 1.16E+00
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 3.09E-01; Fold-change: 2.09E-01; Z-score: 2.20E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2C92	Ureter cancer	Click to Show/Hide
The Studied Tissue	Urothelium
The Specified Disease	Ureter cancer [ICD-11:2C92]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.98E-01; Fold-change: 7.83E-02; Z-score: 1.63E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 2C94	Bladder cancer	Click to Show/Hide
The Studied Tissue	Bladder tissue
The Specified Disease	Bladder cancer [ICD-11:2C94]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.33E-04; Fold-change: -2.03E+00; Z-score: -2.85E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 2D02	Retinal cancer	Click to Show/Hide
The Studied Tissue	Uvea
The Specified Disease	Retinoblastoma [ICD-11:2D02.2]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 7.40E-02; Fold-change: -2.10E-02; Z-score: -1.31E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 2D10	Thyroid cancer	Click to Show/Hide
The Studied Tissue	Thyroid
The Specified Disease	Thyroid cancer [ICD-11:2D10]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 9.83E-01; Fold-change: 3.44E-02; Z-score: 7.14E-02
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 2.18E-01; Fold-change: 8.04E-03; Z-score: 2.79E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 2D11	Adrenal cancer	Click to Show/Hide
The Studied Tissue	Adrenal cortex
The Specified Disease	Adrenocortical carcinoma [ICD-11:2D11.Z]
The Expression Level of Disease Section Compare with the Other Disease Section	p-value: 1.32E-01; Fold-change: 7.27E-01; Z-score: 6.68E-01
DME expression in the diseased tissue of patients DME expression in tissue other than the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of the other disease section
ICD-11: 2D12	Endocrine gland neoplasm	Click to Show/Hide
The Studied Tissue	Pituitary tissue
The Specified Disease	Pituitary cancer [ICD-11:2D12]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.97E-02; Fold-change: -6.76E-01; Z-score: -1.24E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Pituitary tissue
The Specified Disease	Pituitary gonadotrope tumour [ICD-11:2D12]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.17E-03; Fold-change: -7.11E-01; Z-score: -1.33E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 2D42	Head and neck cancer	Click to Show/Hide
The Studied Tissue	Head and neck tissue
The Specified Disease	Head and neck cancer [ICD-11:2D42]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.45E-13; Fold-change: -2.29E+00; Z-score: -1.44E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 03	Blood/blood-forming organ disease	Click to Show/Hide
ICD-11: 3A51	Sickle cell disorder	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Sickle cell disease [ICD-11:3A51.0-3A51.3]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.63E-01; Fold-change: 3.13E-02; Z-score: 2.23E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 3A70	Aplastic anaemia	Click to Show/Hide
The Studied Tissue	Bone marrow
The Specified Disease	Shwachman-Diamond syndrome [ICD-11:3A70.0]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.55E-02; Fold-change: 2.64E-01; Z-score: 1.47E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 3B63	Thrombocytosis	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Thrombocythemia [ICD-11:3B63]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.38E-02; Fold-change: 1.07E-01; Z-score: 8.83E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 3B64	Thrombocytopenia	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Thrombocytopenia [ICD-11:3B64]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 6.38E-01; Fold-change: 1.87E-01; Z-score: 4.94E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 04	Immune system disease	Click to Show/Hide
ICD-11: 4A00	Immunodeficiency	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Immunodeficiency [ICD-11:4A00-4A20]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.27E-02; Fold-change: -1.53E-01; Z-score: -1.32E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 4A40	Lupus erythematosus	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Lupus erythematosus [ICD-11:4A40]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 7.48E-04; Fold-change: -7.04E-02; Z-score: -3.44E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 4A42	Systemic sclerosis	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Scleroderma [ICD-11:4A42.Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.82E-03; Fold-change: 1.20E-01; Z-score: 1.40E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 4A43	Systemic autoimmune disease	Click to Show/Hide
The Studied Tissue	Salivary gland tissue
The Specified Disease	Sjogren's syndrome [ICD-11:4A43.2]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 7.08E-03; Fold-change: 2.15E-01; Z-score: 6.16E+00
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 6.14E-01; Fold-change: -8.38E-03; Z-score: -1.98E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: 4A62	Behcet disease	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Behcet's disease [ICD-11:4A62]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 7.83E-01; Fold-change: -1.88E-02; Z-score: -1.53E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 4B04	Monocyte count disorder	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Autosomal dominant monocytopenia [ICD-11:4B04]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 9.61E-01; Fold-change: 3.84E-02; Z-score: 4.15E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 05	Endocrine/nutritional/metabolic disease	Click to Show/Hide
ICD-11: 5A11	Type 2 diabetes mellitus	Click to Show/Hide
The Studied Tissue	Omental adipose tissue
The Specified Disease	Obesity related type 2 diabetes [ICD-11:5A11]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.96E-01; Fold-change: -4.28E-01; Z-score: -7.54E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Liver tissue
The Specified Disease	Type 2 diabetes [ICD-11:5A11]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 8.58E-01; Fold-change: -3.73E-03; Z-score: -1.00E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 5A80	Ovarian dysfunction	Click to Show/Hide
The Studied Tissue	Vastus lateralis muscle
The Specified Disease	Polycystic ovary syndrome [ICD-11:5A80.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.16E-01; Fold-change: -4.95E-02; Z-score: -6.25E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 5C51	Inborn carbohydrate metabolism disorder	Click to Show/Hide
The Studied Tissue	Biceps muscle
The Specified Disease	Pompe disease [ICD-11:5C51.3]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.17E-03; Fold-change: -2.19E-01; Z-score: -7.01E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 5C56	Lysosomal disease	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Batten disease [ICD-11:5C56.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 8.42E-01; Fold-change: -1.73E-02; Z-score: -1.48E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 5C80	Hyperlipoproteinaemia	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Familial hypercholesterolemia [ICD-11:5C80.00]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.84E-01; Fold-change: -8.92E-03; Z-score: -8.92E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Whole blood
The Specified Disease	Familial hypercholesterolemia [ICD-11:5C80.00]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.65E-02; Fold-change: -8.90E-02; Z-score: -5.58E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 06	Mental/behavioural/neurodevelopmental disorder	Click to Show/Hide
ICD-11: 6A02	Autism spectrum disorder	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Autism [ICD-11:6A02]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.44E-01; Fold-change: -1.07E-02; Z-score: -5.56E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 6A20	Schizophrenia	Click to Show/Hide
The Studied Tissue	Prefrontal cortex
The Specified Disease	Schizophrenia [ICD-11:6A20]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.17E-01; Fold-change: -3.87E-02; Z-score: -2.23E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Superior temporal cortex
The Specified Disease	Schizophrenia [ICD-11:6A20]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 9.74E-01; Fold-change: 7.48E-03; Z-score: 1.37E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 6A60	Bipolar disorder	Click to Show/Hide
The Studied Tissue	Prefrontal cortex
The Specified Disease	Bipolar disorder [ICD-11:6A60-6A6Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.21E-01; Fold-change: -3.94E-02; Z-score: -4.05E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 6A70	Depressive disorder	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Major depressive disorder [ICD-11:6A70-6A7Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 7.63E-01; Fold-change: -1.01E-01; Z-score: -2.77E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Hippocampus
The Specified Disease	Major depressive disorder [ICD-11:6A70-6A7Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.09E-02; Fold-change: -5.62E-02; Z-score: -5.19E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 08	Nervous system disease	Click to Show/Hide
ICD-11: 8A00	Parkinsonism	Click to Show/Hide
The Studied Tissue	Substantia nigra tissue
The Specified Disease	Parkinson's disease [ICD-11:8A00.0]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 9.57E-01; Fold-change: 9.43E-03; Z-score: 1.29E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 8A01	Choreiform disorder	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Huntington's disease [ICD-11:8A01.10]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 6.47E-01; Fold-change: -7.91E-03; Z-score: -1.41E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 8A20	Alzheimer disease	Click to Show/Hide
The Studied Tissue	Entorhinal cortex
The Specified Disease	Alzheimer's disease [ICD-11:8A20]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 9.96E-01; Fold-change: -3.17E-03; Z-score: -1.84E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 8A2Y	Neurocognitive impairment	Click to Show/Hide
The Studied Tissue	White matter tissue
The Specified Disease	HIV-associated neurocognitive impairment [ICD-11:8A2Y-8A2Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.05E-01; Fold-change: -7.09E-02; Z-score: -5.40E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 8A40	Multiple sclerosis	Click to Show/Hide
The Studied Tissue	Plasmacytoid dendritic cells
The Specified Disease	Multiple sclerosis [ICD-11:8A40]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.82E-01; Fold-change: -6.00E-02; Z-score: -2.69E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Spinal cord
The Specified Disease	Multiple sclerosis [ICD-11:8A40]
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 9.06E-01; Fold-change: 4.78E-02; Z-score: 5.65E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
ICD-11: 8A60	Epilepsy	Click to Show/Hide
The Studied Tissue	Peritumoral cortex tissue
The Specified Disease	Epilepsy [ICD-11:8A60-8A6Z]
The Expression Level of Disease Section Compare with the Other Disease Section	p-value: 9.63E-01; Fold-change: 2.58E-02; Z-score: 1.42E-01
DME expression in the diseased tissue of patients DME expression in tissue other than the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of the other disease section
The Studied Tissue	Whole blood
The Specified Disease	Seizure [ICD-11:8A60-8A6Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.67E-03; Fold-change: -1.70E-01; Z-score: -1.36E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 8B01	Subarachnoid haemorrhage	Click to Show/Hide
The Studied Tissue	Intracranial artery
The Specified Disease	Intracranial aneurysm [ICD-11:8B01.0]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.13E-01; Fold-change: -1.95E-01; Z-score: -5.00E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 8B11	Cerebral ischaemic stroke	Click to Show/Hide
The Studied Tissue	Whole blood
The Specified Disease	Cardioembolic stroke [ICD-11:8B11.20]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.22E-01; Fold-change: -6.64E-02; Z-score: -2.91E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Peripheral blood
The Specified Disease	Ischemic stroke [ICD-11:8B11]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.55E-02; Fold-change: 8.53E-02; Z-score: 9.03E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 8B60	Motor neuron disease	Click to Show/Hide
The Studied Tissue	Skin
The Specified Disease	Lateral sclerosis [ICD-11:8B60.4]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.16E-01; Fold-change: 4.53E-02; Z-score: 3.54E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Cervical spinal cord
The Specified Disease	Lateral sclerosis [ICD-11:8B60.4]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.06E-01; Fold-change: -1.87E-01; Z-score: -6.20E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 8C70	Muscular dystrophy	Click to Show/Hide
The Studied Tissue	Muscle tissue
The Specified Disease	Myopathy [ICD-11:8C70.6]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 7.71E-01; Fold-change: -3.83E-02; Z-score: -2.64E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: 8C75	Distal myopathy	Click to Show/Hide
The Studied Tissue	Muscle tissue
The Specified Disease	Tibial muscular dystrophy [ICD-11:8C75]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.88E-01; Fold-change: -2.98E-02; Z-score: -1.92E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 09	Visual system disease	Click to Show/Hide
ICD-11: 9A96	Anterior uveitis	Click to Show/Hide
The Studied Tissue	Peripheral monocyte
The Specified Disease	Autoimmune uveitis [ICD-11:9A96]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 7.19E-01; Fold-change: 3.01E-03; Z-score: 2.72E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 11	Circulatory system disease	Click to Show/Hide
ICD-11: BA41	Myocardial infarction	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Myocardial infarction [ICD-11:BA41-BA50]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.64E-01; Fold-change: -1.08E-01; Z-score: -1.96E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: BA80	Coronary artery disease	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Coronary artery disease [ICD-11:BA80-BA8Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.19E-01; Fold-change: -1.51E-01; Z-score: -8.04E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: BB70	Aortic valve stenosis	Click to Show/Hide
The Studied Tissue	Calcified aortic valve
The Specified Disease	Aortic stenosis [ICD-11:BB70]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 6.25E-01; Fold-change: -1.30E-01; Z-score: -2.70E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 12	Respiratory system disease	Click to Show/Hide
ICD-11: 7A40	Central sleep apnoea	Click to Show/Hide
The Studied Tissue	Hyperplastic tonsil
The Specified Disease	Apnea [ICD-11:7A40]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 6.74E-01; Fold-change: 1.02E+00; Z-score: 9.58E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: CA08	Vasomotor or allergic rhinitis	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Olive pollen allergy [ICD-11:CA08.00]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.04E-01; Fold-change: -2.01E-01; Z-score: -2.41E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: CA0A	Chronic rhinosinusitis	Click to Show/Hide
The Studied Tissue	Sinus mucosa tissue
The Specified Disease	Chronic rhinosinusitis [ICD-11:CA0A]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.82E-01; Fold-change: 9.87E-02; Z-score: 2.50E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: CA22	Chronic obstructive pulmonary disease	Click to Show/Hide
The Studied Tissue	Lung tissue
The Specified Disease	Chronic obstructive pulmonary disease [ICD-11:CA22]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 6.74E-01; Fold-change: 5.99E-02; Z-score: 7.30E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Small airway epithelium
The Specified Disease	Chronic obstructive pulmonary disease [ICD-11:CA22]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.51E-01; Fold-change: 1.59E-01; Z-score: 2.09E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: CA23	Asthma	Click to Show/Hide
The Studied Tissue	Nasal and bronchial airway
The Specified Disease	Asthma [ICD-11:CA23]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.85E-05; Fold-change: 8.08E-01; Z-score: 6.07E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: CB03	Idiopathic interstitial pneumonitis	Click to Show/Hide
The Studied Tissue	Lung tissue
The Specified Disease	Idiopathic pulmonary fibrosis [ICD-11:CB03.4]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.47E-02; Fold-change: -1.30E+00; Z-score: -1.39E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 13	Digestive system disease	Click to Show/Hide
ICD-11: DA0C	Periodontal disease	Click to Show/Hide
The Studied Tissue	Gingival tissue
The Specified Disease	Periodontal disease [ICD-11:DA0C]
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 1.89E-14; Fold-change: -1.11E+00; Z-score: -1.43E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
ICD-11: DA42	Gastritis	Click to Show/Hide
The Studied Tissue	Gastric antrum tissue
The Specified Disease	Eosinophilic gastritis [ICD-11:DA42.2]
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 9.63E-02; Fold-change: -6.65E-01; Z-score: -1.05E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section
ICD-11: DB92	Non-alcoholic fatty liver disease	Click to Show/Hide
The Studied Tissue	Liver tissue
The Specified Disease	Non-alcoholic fatty liver disease [ICD-11:DB92]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.92E-01; Fold-change: 2.42E-01; Z-score: 5.16E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: DB99	Hepatic failure	Click to Show/Hide
The Studied Tissue	Liver tissue
The Specified Disease	Liver failure [ICD-11:DB99.7-DB99.8]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.21E-02; Fold-change: -2.25E+00; Z-score: -2.30E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: DD71	Ulcerative colitis	Click to Show/Hide
The Studied Tissue	Colon mucosal tissue
The Specified Disease	Ulcerative colitis [ICD-11:DD71]
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 1.88E-01; Fold-change: -4.00E-01; Z-score: -5.56E-01
DME expression in the diseased tissue of patients DME expression in tissue other than the diseased tissue of patients
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of the other disease section
ICD-11: DD91	Irritable bowel syndrome	Click to Show/Hide
The Studied Tissue	Rectal colon tissue
The Specified Disease	Irritable bowel syndrome [ICD-11:DD91.0]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 8.83E-03; Fold-change: 1.59E-01; Z-score: 4.32E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 14	Skin disease	Click to Show/Hide
ICD-11: EA80	Atopic eczema	Click to Show/Hide
The Studied Tissue	Skin
The Specified Disease	Atopic dermatitis [ICD-11:EA80]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 4.44E-01; Fold-change: 1.24E-01; Z-score: 2.44E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: EA90	Psoriasis	Click to Show/Hide
The Studied Tissue	Skin
The Specified Disease	Psoriasis [ICD-11:EA90]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.05E-02; Fold-change: 4.52E-01; Z-score: 5.39E-01
The Expression Level of Disease Section Compare with the Adjacent Tissue	p-value: 6.56E-29; Fold-change: -7.92E-01; Z-score: -2.06E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue adjacent to the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data of patients in the normal section of the tissue adjacent to the disease section Download DME expression data in the tissue of healthy individual
ICD-11: ED63	Acquired hypomelanotic disorder	Click to Show/Hide
The Studied Tissue	Skin
The Specified Disease	Vitiligo [ICD-11:ED63.0]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 7.99E-01; Fold-change: -2.86E-01; Z-score: -6.73E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: ED70	Alopecia or hair loss	Click to Show/Hide
The Studied Tissue	Skin from scalp
The Specified Disease	Alopecia [ICD-11:ED70]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.45E-01; Fold-change: -7.02E-02; Z-score: -1.65E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: EK0Z	Contact dermatitis	Click to Show/Hide
The Studied Tissue	Skin
The Specified Disease	Sensitive skin [ICD-11:EK0Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.50E-01; Fold-change: -1.84E-01; Z-score: -5.95E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 15	Musculoskeletal system/connective tissue disease	Click to Show/Hide
ICD-11: FA00	Osteoarthritis	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Arthropathy [ICD-11:FA00-FA5Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.39E-01; Fold-change: 1.04E-01; Z-score: 7.07E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Synovial tissue
The Specified Disease	Osteoarthritis [ICD-11:FA00-FA0Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.31E-01; Fold-change: 7.01E-02; Z-score: 1.11E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: FA20	Rheumatoid arthritis	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Childhood onset rheumatic disease [ICD-11:FA20.Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.36E-01; Fold-change: -1.71E-03; Z-score: -1.84E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
The Studied Tissue	Synovial tissue
The Specified Disease	Rheumatoid arthritis [ICD-11:FA20]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.34E-01; Fold-change: -2.79E-01; Z-score: -7.05E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: FA24	Juvenile idiopathic arthritis	Click to Show/Hide
The Studied Tissue	Peripheral blood
The Specified Disease	Juvenile idiopathic arthritis [ICD-11:FA24]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.02E-01; Fold-change: -1.29E-02; Z-score: -4.99E-02
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: FA92	Inflammatory spondyloarthritis	Click to Show/Hide
The Studied Tissue	Pheripheral blood
The Specified Disease	Ankylosing spondylitis [ICD-11:FA92.0Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.81E-01; Fold-change: -4.28E-02; Z-score: -4.55E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: FB83	Low bone mass disorder	Click to Show/Hide
The Studied Tissue	Bone marrow
The Specified Disease	Osteoporosis [ICD-11:FB83.1]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 1.49E-01; Fold-change: 1.04E-01; Z-score: 1.68E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 16	Genitourinary system disease	Click to Show/Hide
ICD-11: GA10	Endometriosis	Click to Show/Hide
The Studied Tissue	Endometrium tissue
The Specified Disease	Endometriosis [ICD-11:GA10]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 3.74E-03; Fold-change: -6.47E-02; Z-score: -1.18E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: GC00	Cystitis	Click to Show/Hide
The Studied Tissue	Bladder tissue
The Specified Disease	Interstitial cystitis [ICD-11:GC00.3]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 8.33E-04; Fold-change: -2.94E+00; Z-score: -5.55E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 19	Condition originating in perinatal period	Click to Show/Hide
ICD-11: KA21	Short gestation disorder	Click to Show/Hide
The Studied Tissue	Myometrium
The Specified Disease	Preterm birth [ICD-11:KA21.4Z]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 6.54E-01; Fold-change: -1.92E-01; Z-score: -5.38E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD Disease Classification 20	Developmental anomaly	Click to Show/Hide
ICD-11: LD2C	Overgrowth syndrome	Click to Show/Hide
The Studied Tissue	Adipose tissue
The Specified Disease	Simpson golabi behmel syndrome [ICD-11:LD2C]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 5.57E-01; Fold-change: 5.26E-02; Z-score: 5.21E-01
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual
ICD-11: LD2D	Phakomatoses/hamartoneoplastic syndrome	Click to Show/Hide
The Studied Tissue	Perituberal tissue
The Specified Disease	Tuberous sclerosis complex [ICD-11:LD2D.2]
The Expression Level of Disease Section Compare with the Healthy Individual Tissue	p-value: 2.85E-02; Fold-change: 1.19E-01; Z-score: 3.43E+00
DME expression in the diseased tissue of patients DME expression in the normal tissue of healthy individuals
Violin Diagram of DME Disease-specific Protein Abundances		Click to View the Clearer Original Diagram
Download DME expression barchart for all samples Download DME expression data of patients in the disease section of the tissue Download DME expression data in the tissue of healthy individual

References
1	Human liver microsomal cytochrome P450 3A enzymes involved in thalidomide 5-hydroxylation and formation of a glutathione conjugate. Chem Res Toxicol. 2010 Jun 21;23(6):1018-24.
2	Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther. 2010 Mar;87(3):322-9.
3	Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
4	Metabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humans
5	Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009 Dec;35(8):692-706.
6	Cytochrome P450-mediated metabolism of estrogens and its regulation in human Cancer Lett. 2005 Sep 28;227(2):115-24. doi: 10.1016/j.canlet.2004.10.007.
7	A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
8	Drug Interactions Flockhart Table
9	16Alpha-hydroxylation of estrone by human cytochrome P4503A4/5. Carcinogenesis. 1998 May;19(5):867-72.
10	Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos. 2005 Jun;33(6):764-70.
11	Regenerative changes in hepatic morphology and enhanced expression of CYP2B10 and CYP3A during daily administration of cocaine. Hepatology. 1996 Mar;23(3):515-23.
12	PubChem:Pimavanserin
13	Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator
14	Daclatasvir: a NS5A replication complex inhibitor for hepatitis C infection. Ann Pharmacother. 2016 Jan;50(1):39-46.
15	Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. J Pharmacokinet Biopharm. 1999 Feb;27(1):1-21.
16	Construction and verification of CYP3A5 gene polymorphisms using a Saccharomyces cerevisiae expression system to predict drug metabolism. Mol Med Rep. 2017 Apr;15(4):1593-1600.
17	Absorption, metabolism, and excretion of oral 14C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men. Drug Metab Dispos. 2015 Feb;43(2):289-97.
18	Exploring the metabolism of loxoprofen in liver microsomes: the role of cytochrome P450 and UDP-glucuronosyltransferase in its biotransformation. Pharmaceutics. 2018 Aug 2;10(3). pii: E112.
19	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
20	In vitro metabolism of montelukast by cytochrome P450s and UDP-glucuronosyltransferases. Drug Metab Dispos. 2015 Dec;43(12):1905-16.
21	Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
22	FDA label of Acalabrutinib. The 2020 official website of the U.S. Food and Drug Administration.
23	Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm. 2013 Jun 1;70(11):943-7.
24	Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
25	The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
26	Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev. 2014 Feb;46(1):86-95.
27	CYP3A418B and CYP3A53 polymorphisms contribute to pharmacokinetic variability of cyclosporine among healthy Chinese subjects. Eur J Pharm Sci. 2015 Aug 30;76:238-44.
28	Metabolic Pathway of Cyclosporine A and Its Correlation with Nephrotoxicity
29	Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans. Xenobiotica. 2019 Apr;49(4):422-432.
30	Sulfotransferase 1E1 is a low km isoform mediating the 3-O-sulfation of ethinyl estradiol Drug Metab Dispos. 2004 Nov;32(11):1299-303. doi: 10.1124/dmd.32.11..
31	Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res. 1997 May 15;57(10):1946-54.
32	PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
33	Cytochromes P450 1A2 and 3A4 Catalyze the Metabolic Activation of Sunitinib
34	Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. Fundam Clin Pharmacol. 2007 Aug;21(4):427-35.
35	Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
36	DAILYMED.nlm.nih.gov: JEVTANA- cabazitaxel kit.
37	Identification of the human P-450 enzymes responsible for the sulfoxidation and thiono-oxidation of diethyldithiocarbamate methyl ester: role of P-450 enzymes in disulfiram bioactivation. Alcohol Clin Exp Res. 1998 Sep;22(6):1212-9.
38	Product Monograph of Xtandi.
39	Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004 Apr;32(4):447-54.
40	Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug Metab Dispos. 1999 Feb;27(2):173-9.
41	Pharmacology of the new target-specific oral anticoagulants. J Thromb Thrombolysis. 2013 Aug;36(2):133-40.
42	The pharmacology and clinical pharmacokinetics of apomorphine SL BJU Int. 2001 Oct;88 Suppl 3:18-21. doi: 10.1046/j.1464-4096.2001.00124.x.
43	Activation of beclomethasone dipropionate by hydrolysis to beclomethasone-17-monopropionate
44	Degradation products of beclomethasone dipropionate in human plasma
45	Comparative kinetics of metabolism of beclomethasone propionate esters in human lung homogenates and plasma
46	Genetic polymorphism of cytochrome P450 2D6 determines oestrogen receptor activity of the major infertility drug clomiphene via its active metabolites
47	CYP3A Specifically Catalyzes 1-Hydroxylation of Deoxycholic Acid: Characterization and Enzymatic Synthesis of a Potential Novel Urinary Biomarker for CYP3A Activity
48	CYP3A5 genotype is associated with elevated blood pressure. Pharmacogenet Genomics. 2005 Oct;15(10):737-41.
49	Enzymes in addition to CYP3A4 and 3A5 mediate N-demethylation of dextromethorphan in human liver microsomes. Biopharm Drug Dispos. 1999 Oct;20(7):341-6.
50	Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor Drug Metab Dispos. 2016 Aug;44(8):1201-12. doi: 10.1124/dmd.115.069203.
51	FDA label of Perampanel. The 2020 official website of the U.S. Food and Drug Administration.
52	Mass balance, pharmacokinetics and metabolism of the selective S1P1 receptor modulator ponesimod in humans
53	DrugBank(Pharmacology-Metabolism):Ponesimod
54	Verapamil toxicity resulting from a probable interaction with telithromycin. Ann Pharmacother. 2005 Feb;39(2):357-60.
55	O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol. 1994 Feb;45(2):352-8.
56	Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010 Sep;38(9):1514-21.
57	Metabolism of ticagrelor in patients with acute coronary syndromes
58	Elimination of tucatinib, a small molecule kinase inhibitor of HER2, is primarily governed by CYP2C8 enantioselective oxidation of gem-dimethyl
59	Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin Pharmacol Ther. 2007 Oct;82(4):410-26.
60	Metabolism of beta-arteether to dihydroqinghaosu by human liver microsomes and recombinant cytochrome P450
61	Clinical pharmacology of axitinib. Clin Pharmacokinet. 2013 Sep;52(9):713-25.
62	Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies. Drug Metab Dispos. 2000 Jul;28(7):789-800.
63	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
64	Eight inhibitory monoclonal antibodies define the role of individual P-450s in human liver microsomal diazepam, 7-ethoxycoumarin, and imipramine metabolism. Drug Metab Dispos. 1999 Jan;27(1):102-9.
65	Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A41B and 3A53 for 25 fentanyl cases J Anal Toxicol. 2005 Oct;29(7):590-8. doi: 10.1093/jat/29.7.590.
66	Identification of a novel glutathione conjugate of flutamide in incubations with human liver microsomes. Drug Metab Dispos. 2007 Jul;35(7):1081-8.
67	Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metab Dispos. 2003 Mar;31(3):243-9.
68	Identification of the human P450 enzymes involved in lansoprazole metabolism J Pharmacol Exp Ther. 1996 May;277(2):805-16.
69	Disposition of lasofoxifene, a next-generation selective estrogen receptor modulator, in healthy male subjects
70	DrugBank(Pharmacology-Metabolism):Lasofoxifene
71	[Influence of CYP3A4/5 polymorphisms in the pharmacokinetics of levonorgestrel: a pilot study] Biomedica. 2012 Oct-Dec;32(4):570-7. doi: 10.1590/S0120-41572012000400012.
72	The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther. 2003 Dec;74(6):525-35.
73	Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans. Drug Metab Dispos. 1995 Nov;23(11):1225-30.
74	The influence of diltiazem versus cimetidine on propranolol metabolism. J Clin Pharmacol. 1992 Dec;32(12):1099-104.
75	Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
76	Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7. Biochem Pharmacol. 2003 Dec 15;66(12):2333-40.
77	Oxidative metabolism of amprenavir in the human liver. Effect of the CYP3A maturation. Drug Metab Dispos. 2003 Mar;31(3):275-81.
78	Effect of pharmacogenetics on plasma lumefantrine pharmacokinetics and malaria treatment outcome in pregnant women. Malar J. 2017 Jul 3;16(1):267.
79	Metabolite Profiling and Reaction Phenotyping for the in Vitro Assessment of the Bioactivation of Bromfenac ? Chem Res Toxicol. 2020 Jan 21;33(1):249-257. doi: 10.1021/acs.chemrestox.9b00268.
80	Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos. 2005 Apr;33(4):500-7.
81	Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor. Biol Pharm Bull. 2003 Apr;26(4):510-7.
82	FDA label of Cenobamate. The 2020 official website of the U.S. Food and Drug Administration.
83	Comparative pharmacokinetics and metabolism studies in lean and diet- induced obese mice: an animal efficacy model for 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors. Drug Metab Lett. 2011 Jan;5(1):55-63.
84	Significant impacts of CYP3A41G and CYP3A53 genetic polymorphisms on the pharmacokinetics of diltiazem and its main metabolites in Chinese adult kidney transplant patients. J Clin Pharm Ther. 2016 Jun;41(3):341-7.
85	Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
86	Inactivation of human cytochrome P450 3A4 and 3A5 by dronedarone and N-desbutyl dronedarone. Mol Pharmacol. 2016 Jan;89(1):1-13.
87	(R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos. 2000 Oct;28(10):1187-91.
88	Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics. 2004 Aug;14(8):523-5.
89	Effects of rifampin on the pharmacokinetics of a single dose of istradefylline in healthy subjects. J Clin Pharmacol. 2018 Feb;58(2):193-201.
90	Identification of the metabolites of ivermectin in humans Pharmacol Res Perspect. 2021 Feb;9(1):e00712. doi: 10.1002/prp2.712.
91	Absorption, Metabolism, Distribution, and Excretion of Letermovir Curr Drug Metab. 2021;22(10):784-794. doi: 10.2174/1389200222666210223112826.
92	In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of cyp3a4 and cyp3a5. Drug Metab Dispos. 2003 Jul;31(7):938-44.
93	PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
94	Human biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison. Antimicrob Agents Chemother. 2013 Oct;57(10):5067-79.
95	In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos. 1997 Oct;25(10):1191-9.
96	DrugBank(Pharmacology-Metabolism):Simvastatin
97	A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry
98	Absorption, distribution, metabolism, and excretion of [1?C]GDC-0449 (vismodegib), an orally active hedgehog pathway inhibitor, in rats and dogs: a unique metabolic pathway via pyridine ring opening
99	Preclinical assessment of the absorption, distribution, metabolism and excretion of GDC-0449 (2-chloro-N-(4-chloro-3-(pyridin-2-yl)phenyl)-4-(methylsulfonyl)benzamide), an orally bioavailable systemic Hedgehog signalling pathway inhibitor
100	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA166170041)
101	In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec;70(6):854-69.
102	Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban. J Clin Pharmacol. 1999 May;39(5):513-9.
103	Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res. 2006 Mar;23(3):506-12.
104	Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos. 1999 Dec;27(12):1381-91.
105	Buprenorphine pharmacology review: update on transmucosal and long-acting formulations. J Addict Med. 2019 Mar/Apr;13(2):93-103.
106	Characterization of Clofazimine Metabolism in Human Liver Microsomal Incubation In Vitro
107	CYP2D6 mediates 4-hydroxylation of clonidine in vitro: implication for pregnancy-induced changes in clonidine clearance. Drug Metab Dispos. 2010 Sep;38(9):1393-6.
108	Population pharmacokinetics of doxapram in low-birth-weight Japanese infants with apnea. Eur J Pediatr. 2015 Apr;174(4):509-18.
109	Pharmacogenomics as molecular autopsy for forensic toxicology: genotyping cytochrome P450 3A41B and 3A53 for 25 fentanyl cases. J Anal Toxicol. 2005 Oct;29(7):590-8.
110	In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine. Biopharm Drug Dispos. 2011 Oct;32(7):398-407.
111	Metabolic Disposition of Lurbinectedin, a Potent Selective Inhibitor of Active Transcription of Protein-Coding Genes, in Nonclinical Species and Patients
112	Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5. Xenobiotica. 2006 Apr;36(4):287-99.
113	Ema.europa:Nalmefene
114	Impact of intestinal CYP2C19 genotypes on the interaction between tacrolimus and omeprazole, but not lansoprazole, in adult living-donor liver transplant patients. Drug Metab Dispos. 2009 Apr;37(4):821-6.
115	CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone
116	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development Curr Med Chem. 2009;16(27):3480-675. doi: 10.2174/092986709789057635.
117	Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia. Onco Targets Ther. 2013 Aug 20;6:1111-8.
118	Influence of cytochrome P450 genotype on the plasma disposition of prochlorperazine metabolites and their relationships with clinical responses in cancer patients Ann Clin Biochem. 2018 May;55(3):385-393. doi: 10.1177/0004563217731432.
119	Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers. Pharmacogenet Genomics. 2014 Jan;24(1):35-42.
120	Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol. 2006 Jan;98(1):79-85.
121	Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
122	Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65.
123	Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
124	Identification and phenotype characterization of two CYP3A haplotypes causing different enzymatic capacity in fetal livers. Clin Pharmacol Ther. 2005 Apr;77(4):259-70.
125	Apixaban. After hip or knee replacement: LMWH remains the standard treatment. Prescrire Int. 2012 Sep;21(130):201-2, 204.
126	FDA label:Avapritinib
127	Optimization of Clonazepam Therapy Adjusted to Patient's CYP3A Status and NAT2 Genotype
128	Product monograph: Avodart (dutasteride capsules).
129	DrugBank(Pharmacology-Metabolism):Dutasteride
130	Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
131	Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res. 2007 Jun 15;13(12):3731-7.
132	Application of liquid chromatography/mass spectrometry in accelerating the identification of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J Pharmacol Exp Ther. 1998 Sep;286(3):1285-93.
133	Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol In Vitro. 2006 Mar;20(2):163-75.
134	The impact of individual human cytochrome P450 enzymes on oxidative metabolism of anticancer drug lenvatinib
135	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
136	Methadone metabolism and drug-drug interactions: in vitro and in vivo literature review. J Pharm Sci. 2018 Dec;107(12):2983-2991.
137	Pharmacogenomics knowledge for personalized medicine Clin Pharmacol Ther. 2012 Oct;92(4):414-7. doi: 10.1038/clpt.2012.96.
138	Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit. 2004 Dec;26(6):600-8.
139	DrugBank(Pharmacology-Metabolism):Mycophenolic acid
140	Enzyme kinetics and inhibition of nimodipine metabolism in human liver microsomes. Acta Pharmacol Sin. 2000 Aug;21(8):690-4.
141	Pharmacokinetics, metabolism and excretion of intravenous [l4C]-palonosetron in healthy human volunteers Biopharm Drug Dispos. 2004 Nov;25(8):329-37. doi: 10.1002/bdd.410.
142	An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid. Br J Clin Pharmacol. 2006 May;61(5):570-84.
143	Induction and regulation of xenobiotic-metabolizing cytochrome P450s in the human A549 lung adenocarcinoma cell line. Am J Respir Cell Mol Biol. 2000 Mar;22(3):360-6.
144	Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat
145	The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human
146	Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem Pharmacol. 2007 Jun 15;73(12):2020-6.
147	Effect of ketoconazole on the pharmacokinetic profile of ambrisentan. J Clin Pharmacol. 2009 Jun;49(6):719-24.
148	Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet. 2003;42(2):123-37.
149	Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol. 2013;53:427-49.
150	Effects of CYP3A inhibition on the metabolism of cilostazol. Clin Pharmacokinet. 1999;37 Suppl 2:61-8.
151	In vitro metabolism of clindamycin in human liver and intestinal microsomes. Drug Metab Dispos. 2003 Jul;31(7):878-87.
152	Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007 May;81(5):735-41.
153	The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
154	Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br J Clin Pharmacol. 1994 Dec;38(6):557-66.
155	Pharmacokinetic Evaluation of CYP3A4-Mediated Drug-Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults Clin Pharmacol Drug Dev. 2017 Jan;6(1):44-53. doi: 10.1002/cpdd.285.
156	Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer. Pediatr Pulmonol. 2018 May;53(5):E6-E8.
157	Metabolism of loratadine and further characterization of its in vitro metabolites. Drug Metab Lett. 2009 Aug;3(3):162-70.
158	Metabolism of megestrol acetate in vitro and the role of oxidative metabolites Xenobiotica. 2018 Oct;48(10):973-983. doi: 10.1080/00498254.2017.1386335.
159	Species differences in stereoselective metabolism of mephenytoin by cytochrome P450 (CYP2C and CYP3A). J Pharmacol Exp Ther. 1993 Jan;264(1):89-94.
160	Cytochrome P450 enzyme activity and protein expression in primary porcine enterocyte and hepatocyte cultures. Xenobiotica. 2000 Jan;30(1):27-46.
161	Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metab Dispos. 2001 Oct;29(10):1263-8.
162	Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
163	In vitro metabolic profile and drug-drug interaction assessment of secnidazole, a high-dose 5-nitroimidazole antibiotic for the treatment of bacterial vaginosis Pharmacol Res Perspect. 2020 Aug;8(4):e00634. doi: 10.1002/prp2.634.
164	The contributions of cytochromes P450 3A4 and 3A5 to the metabolism of the phosphodiesterase type 5 inhibitors sildenafil, udenafil, and vardenafil. Drug Metab Dispos. 2008 Jun;36(6):986-90.
165	Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily Xenobiotica. 1996 Nov;26(11):1155-66. doi: 10.3109/00498259609050260.
166	FDA Approved Drug Products:Oxbryta (voxelotor) tablets
167	Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data. Eur J Clin Pharmacol. 1998 Apr;54(2):177-83.
168	Aztreonam decreases hepatic microsomal cytochrome P450 in cynomolgus monkeys. Pharmacology. 1994 Mar;48(3):137-42.
169	Product monograph: LUMIGAN RC (Bimatoprost).
170	Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Arch Pharm Res. 2003 Aug;26(8):631-7.
171	Metabolism and Interactions of Chloroquine and Hydroxychloroquine with Human Cytochrome P450 Enzymes and Drug Transporters Curr Drug Metab. 2020;21(14):1127-1135. doi: 10.2174/1389200221999201208211537.
172	Differential regulation of CYP3A4 and CYP3A5 and its implication in drug discovery. Curr Drug Metab. 2017;18(12):1095-1105.
173	Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids. Drug Metab Rev. 2010 Nov;42(4):621-35.
174	The inhaled glucocorticoid fluticasone propionate efficiently inactivates cytochrome P450 3A5, a predominant lung P450 enzyme. Chem Res Toxicol. 2010 Aug 16;23(8):1356-64.
175	Fluticasone propionate pharmacogenetics: CYP3A4*22 polymorphism and pediatric asthma control
176	Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5. J Pharm Pharmacol. 1999 Apr;51(4):419-26.
177	Prevention of preterm delivery with 17-hydroxyprogesterone caproate: pharmacologic considerations. Semin Perinatol. 2014 Dec;38(8):516-22.
178	Product characteristics of HYDROXYZINE (Hydroxyzine Hydrochloride Capsules).
179	Identification of human liver cytochrome P450 enzymes responsible for the metabolism of lonafarnib (Sarasar). Drug Metab Dispos. 2006 Apr;34(4):628-35.
180	FDA label of Lorlatinib. The 2020 official website of the U.S. Food and Drug Administration.
181	Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67.
182	Stereoselective pharmacokinetics of oxybutynin and N-desethyloxybutynin in vitro and in vivo. Xenobiotica. 2007 Jan;37(1):59-73.
183	Pimecrolimus: absorption, distribution, metabolism, and excretion in healthy volunteers after a single oral dose and supplementary investigations in vitro. Drug Metab Dispos. 2006 May;34(5):765-74.
184	Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin Pharmacol Ther. 2002 Nov;72(5):505-13.
185	Effects of CYP3A Inhibition, CYP3A Induction, and Gastric Acid Reduction on the Pharmacokinetics of Ripretinib, a Switch Control KIT Tyrosine Kinase Inhibitor
186	Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin Cancer Res. 2009 Feb 15;15(4):1496-503.
187	Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in healthy subjects. Br J Clin Pharmacol. 2011 Jul;72(1):92-102.
188	Contribution of CYP3A isoforms to dealkylation of PDE5 inhibitors: a comparison between sildenafil N-demethylation and tadalafil demethylenation. Biol Pharm Bull. 2015;38(1):58-65.
189	FDA label of Tenapanor. The 2020 official website of the U.S. Food and Drug Administration.
190	Metabolic pathways of inhaled glucocorticoids by the CYP3A enzymes. Drug Metab Dispos. 2013 Feb;41(2):379-89.
191	Association of CYP3A5 expression and vincristine neurotoxicity in pediatric malignancies in Turkish population. J Pediatr Hematol Oncol. 2017 Aug;39(6):458-462.
192	Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997 Mar;32(3):194-209.
193	Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells. J Pharmacol Exp Ther. 2003 Feb;304(2):745-52.
194	Genetic variation in the first-pass metabolism of ethinylestradiol, sex hormone binding globulin levels and venous thrombosis risk Eur J Intern Med. 2017 Jul;42:54-60. doi: 10.1016/j.ejim.2017.05.019.
195	Metabolism of 17 alpha-ethinylestradiol by human liver microsomes in vitro: aromatic hydroxylation and irreversible protein binding of metabolites J Clin Endocrinol Metab. 1974 Dec;39(6):1072-80. doi: 10.1210/jcem-39-6-1072.
196	Identification of CYP3A7 for glyburide metabolism in human fetal livers. Biochem Pharmacol. 2014 Dec 15;92(4):690-700.
197	Characterisation of seven medications approved for attention-deficit/hyperactivity disorder using in?vitro models of hepatic metabolism
198	Inhibitory Effect of Vonoprazan on the Metabolism of [(14)C]Prasugrel in Human Liver Microsomes
199	Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218.
200	Characterization of benidipine and its enantiomers' metabolism by human liver cytochrome P450 enzymes. Drug Metab Dispos. 2007 Sep;35(9):1518-24.
201	Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites J Pharmacol Exp Ther. 2017 Jun;361(3):454-461. doi: 10.1124/jpet.116.239160.
202	CYP3A5*3 and MDR1 C3435T are influencing factors of inter-subject variability in rupatadine pharmacokinetics in healthy Chinese volunteers. Eur J Drug Metab Pharmacokinet. 2016 Apr;41(2):117-24.
203	Effect of CYP3A5*3 genetic variant on the metabolism of direct-acting antivirals in vitro: a different effect on asunaprevir versus daclatasvir and beclabuvir J Hum Genet. 2020 Jan;65(2):143-153. doi: 10.1038/s10038-019-0685-2.
204	Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
205	Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose Regimens
206	Human liver S9 fractions: metabolism of dehydroepiandrosterone, epiandrosterone, and related 7-hydroxylated derivatives
207	Characterization of ADME properties of [(14)C]asunaprevir (BMS-650032) in humans. Xenobiotica. 2016;46(1):52-64.
208	Stereoselective hydroxylation by CYP2C19 and oxidation by ADH4 in the in vitro metabolism of tivantinib
209	Metabolic pathway of icotinib in vitro: the differential roles of CYP3A4, CYP3A5, and CYP1A2 on potential pharmacokinetic drug-drug interaction. J Pharm Sci. 2018 Apr;107(4):979-983.
210	The metabolic profile of azimilide in man: in vivo and in vitro evaluations. J Pharm Sci. 2005 Sep;94(9):2084-95.
211	CYP26C1 is a hydroxylase of multiple active retinoids and interacts with cellular retinoic acid binding proteins. Mol Pharmacol. 2018 May;93(5):489-503.
212	Metabolism and Disposition of [(14)C]Pevonedistat, a First-in-Class NEDD8-Activating Enzyme Inhibitor, after Intravenous Infusion to Patients with Advanced Solid Tumors
213	Trastuzumab emtansine. An inadequately assessed combination of two cytotoxic drugs. Prescrire Int. 2014 Dec;23(155):289.
214	Disposition and metabolism of the G protein-coupled receptor 40 agonist TAK-875 (fasiglifam) in rats, dogs, and humans. Xenobiotica. 2019 Apr;49(4):433-445.
215	Pharmacokinetic and drug-drug interaction profiles of the combination of Tezacaftor/Ivacaftor. Clin Transl Sci. 2019 May;12(3):267-275.
216	CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels. Clin Pharmacol Ther. 2004 Jun;75(6):516-28.
217	Effect of glycyrrhizin on the activity of CYP3A enzyme in humans. Eur J Clin Pharmacol. 2010 Aug;66(8):805-810.
218	Disposition and metabolism of semagacestat, a {gamma}-secretase inhibitor, in humans. Drug Metab Dispos. 2010 Apr;38(4):554-65.
219	Pharmacokinetic profile of dexloxiglumide. Clin Pharmacokinet. 2006;45(12):1177-88.
220	In vitro evaluation of fenfluramine and norfenfluramine as victims of drug interactions
221	Characterization of the cytochrome P-450 gene family responsible for the N-dealkylation of the ergot alkaloid CQA 206-291 in humans
222	Induction of cytochromes P-450 2B and 3A in mice following the dietary administration of the novel cognitive enhancer linopirdine. Drug Metab Dispos. 1994 Jan-Feb;22(1):65-73.
223	DrugBank(Pharmacology-Metabolism):Ganaxolone
224	Effect of ketoconazole on the pharmacokinetics of ornidazole--a possible role of p-glycoprotein and CYP3A. Drug Metabol Drug Interact. 2006;22(1):67-77.
225	Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development. J Hematol Oncol. 2018 Sep 19;11(1):120.
226	Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin. Drug Metab Dispos. 2000 Nov;28(11):1369-78.
227	In vitro and in vivo metabolism and pharmacokinetics of BMS-562086, a potent and orally bioavailable corticotropin-releasing factor-1 receptor antagonist
228	The disposition of three phosphodiesterase type 5 inhibitors, vardenafil, sildenafil, and udenafil, is differently influenced by the CYP3A5 genotype. Pharmacogenet Genomics. 2011 Dec;21(12):820-8.
229	Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies
230	Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLoS Negl Trop Dis. 2010 Dec 21;4(12):e923.
231	Structural perspectives of the CYP3A family and their small molecule modulators in drug metabolism. 2019, 3(3), 132-142.
232	CYP3A but not P-gp plays a relevant role in the in vivo intestinal and hepatic clearance of the delta-specific phosphoinositide-3 kinase inhibitor leniolisib
233	Minor contribution of CYP3A5 to the metabolism of hepatitis C protease inhibitor paritaprevir in vitro
234	Main protease inhibitors and drug surface hotspots for the treatment of COVID-19: A drug repurposing and molecular docking approach
235	The Effect of Modafinil on the Safety and Pharmacokinetics of Lorlatinib: A Phase I Study in Healthy Participants
236	First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor AZD2014. Clin Cancer Res. 2015 Aug 1;21(15):3412-9.
237	Quinacrine is mainly metabolized to mono-desethyl quinacrine by CYP3A4/5 and its brain accumulation is limited by P-glycoprotein. Drug Metab Dispos. 2006 Jul;34(7):1136-44.
238	Metabolic pathways of the camptothecin analog AR-67
239	In vitro assessment of metabolic drugCdrug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P(450) enzyme identification, inhibition, and induction studies
240	Population pharmacokinetics of telapristone (CDB-4124) and its active monodemethylated metabolite CDB-4453, with a mixture model for total clearance
241	Physiologically based pharmacokinetic modeling to predict complex drug-drug interactions: a case study of AZD2327 and its metabolite, competitive and time-dependent CYP3A inhibitors
242	The Drug-Drug Interaction Profile of Presatovir
243	Safety assessment, in vitro and in vivo, and pharmacokinetics of emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2000 Jan;44(1):123-30.
244	The pharmacogenetics of the new-generation antipsychotics - A scoping review focused on patients with severe psychiatric disorders
245	Simulation of human plasma concentration-time profiles of the partial glucokinase activator PF-04937319 and its disproportionate N-demethylated metabolite using humanized chimeric mice and semi-physiological pharmacokinetic modeling
246	Pre-clinical Characterization of Absorption, Distribution, Metabolism and Excretion Properties of TAK-063
247	Pharmacokinetics and Safety After a Single Dose of Imarikiren in Subjects with Renal or Hepatic Impairment
248	Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects
249	Discovery of Encequidar, First-in-Class Intestine Specific P-glycoprotein Inhibitor
250	Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
251	Metabolic map and bioactivation of the anti-tumour drug noscapine
252	Assessment of drug-drug interaction potential and PBPK modeling of CC-223, a potent inhibitor of the mammalian target of rapamycin kinase. Xenobiotica. 2019 Jan;49(1):54-70.
253	Metabolism Of Antiretroviral Drugs Used In Hiv Preexposure Prophylaxis
254	In vitro metabolism of irosustat, a novel steroid sulfatase inhibitor: interspecies comparison, metabolite identification, and metabolic enzyme identification
255	Metabolism and pharmacokinetics of allitinib in cancer patients: the roles of cytochrome P450s and epoxide hydrolase in its biotransformation
256	Pharmacokinetics and Metabolism of Naringin and Active Metabolite Naringenin in Rats, Dogs, Humans, and the Differences Between Species
257	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
258	Metabolites of PPI-2458, a selective, irreversible inhibitor of methionine aminopeptidase-2: structure determination and in vivo activity. Drug Metab Dispos. 2013 Apr;41(4):814-26.
259	In vitro metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin in human liver microsomes
260	In vitro and in vivo clinical pharmacology of dimethyl benzoylphenylurea, a novel oral tubulin-interactive agent
261	Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours
262	In Vitro Metabolic Pathways of the New Anti-Diabetic Drug Evogliptin in Human Liver Preparations
263	CYP3A5 mediates bioactivation and cytotoxicity of tetrandrine. Arch Toxicol. 2016 Jul;90(7):1737-48.
264	Correlation of the in vitro biotransformation of H3B-6527 in dog and human hepatocytes with the in vivo metabolic profile of 14C-H3B-6527 in a dog mass balance study. Xenobiotica. 2020 Apr;50(4):458-467.
265	ITX 5061 quantitation in human plasma with reverse phase liquid chromatography and mass spectrometry detection. Antivir Ther. 2013;18(3):329-36.
266	In vitro metabolism of 7 neuronal nicotinic receptor agonist AZD0328 and enzyme identification for its N-oxide metabolite
267	In vivo production of novel vitamin D2 hydroxy-derivatives by human placentas, epidermal keratinocytes, Caco-2 colon cells and the adrenal gland. Mol Cell Endocrinol. 2014 Mar 5;383(1-2):181-92. doi: 10.1016/j.mce.2013.12.012.
268	Species-dependent metabolism of a novel selective 7 neuronal acetylcholine receptor agonist ABT-107
269	Metabolism of ezlopitant, a nonpeptidic substance P receptor antagonist, in liver microsomes: enzyme kinetics, cytochrome P450 isoform identity, and in vitro-in vivo correlation. Drug Metab Dispos. 2000 Sep;28(9):1069-76.
270	Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care
271	Diazinon, chlorpyrifos and parathion are metabolised by multiple cytochromes P450 in human liver. Toxicology. 2006 Jul 5;224(1-2):22-32.
272	Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes. Drug Metab Dispos. 2005 Mar;33(3):303-11.
273	Potential for pharmacokinetic interactions between ambrisentan and cyclosporine. Clin Pharmacol Ther. 2010 Oct;88(4):513-20.
274	Apixaban. Hosp Pharm. 2013 Jun;48(6):494-509.
275	LABEL:RMODAFINIL tablet
276	Synthesis, characterization, and antimalarial activity of the glucuronides of the hydroxylated metabolites of arteether
277	Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz In Silico Pharmacol. 2013 Mar 1;1:4. doi: 10.1186/2193-9616-1-4.
278	In Vitro Kinetic Characterization of Axitinib Metabolism
279	Phase I study of orally administered (14)Carbon-isotope labelled-vistusertib (AZD2014), a dual TORC1/2 kinase inhibitor, to assess the absorption, metabolism, excretion, and pharmacokinetics in patients with advanced solid malignancies
280	Examination of metabolic pathways and identification of human liver cytochrome P450 isozymes responsible for the metabolism of barnidipine, a calcium channel blocker. Xenobiotica. 1997 Sep;27(9):885-900.
281	DrugBank(Pharmacology-Metabolism):Beclomethasone dipropionate
282	Metabolism of beclomethasone dipropionate by cytochrome P450 3A enzymes. J Pharmacol Exp Ther. 2013 May;345(2):308-16.
283	DrugBank(Pharmacology-Metabolism)Asunaprevir
284	Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor
285	Metabolism of carfentanil, an ultra-potent opioid, in human liver microsomes and human hepatocytes by high-resolution mass spectrometry. AAPS J. 2016 Nov;18(6):1489-1499.
286	Metabolite profiling and reaction phenotyping for the in vitro assessment of the bioactivation of bromfenac. Chem Res Toxicol. 2020 Jan 21;33(1):249-257.
287	Metabolic disposition of 14C-bromfenac in healthy male volunteers J Clin Pharmacol. 1998 Aug;38(8):744-52. doi: 10.1002/j.1552-4604.1998.tb04815.x.
288	In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos. 2005 May;33(5):689-95.
289	DrugBank(Pharmacology-Metabolism)Buspirone
290	A phase I open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumors Anticancer Drugs. 2015 Mar;26(3):350-8. doi: 10.1097/CAD.0000000000000185.
291	Carbamazepine and its metabolites in human perfused placenta and in maternal and cord blood Epilepsia. 1995 Mar;36(3):241-8. doi: 10.1111/j.1528-1157.1995.tb00991.x.
292	Identification of human hepatic cytochrome p450 enzymes involved in the biotransformation of cholic and chenodeoxycholic acid. Drug Metab Dispos. 2008 Oct;36(10):1983-91.
293	Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements Clin Pharmacokinet. 1996 Oct;31(4):257-74. doi: 10.2165/00003088-199631040-00003.
294	Cyclosporin metabolism in transplant patients
295	Determination of cilostazol and its metabolites in human urine by high performance liquid chromatography J Pharm Biomed Anal. 2001 Jan;24(3):381-9. doi: 10.1016/s0731-7085(00)00426-x.
296	Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol Drug Metab Dispos. 2007 Oct;35(10):1730-2. doi: 10.1124/dmd.107.016758.
297	Metabolism, pharmacokinetics, and excretion of a nonpeptidic substance P receptor antagonist, ezlopitant, in normal healthy male volunteers: characterization of polar metabolites by chemical derivatization with dansyl chloride
298	Study on the Pharmacokinetics of Diazepam and Its Metabolites in Blood of Chinese People Eur J Drug Metab Pharmacokinet. 2020 Aug;45(4):477-485. doi: 10.1007/s13318-020-00614-8.
299	Pharmacokinetics of Diazepam and Its Metabolites in Urine of Chinese Participants. Drugs R D. 2022 Mar;22(1):43-50. doi: 10.1007/s40268-021-00375-y.
300	Kinetic disposition of diazepam and its metabolites after intravenous administration of diazepam in the horse: Relevance for doping control. J Vet Pharmacol Ther. 2021 Sep;44(5):733-744. doi: 10.1111/jvp.12991.
301	DrugBank(Pharmacology-Metabolism)Diazepam
302	Drug Interactions Flockhart Table:Docetaxel
303	DrugBank(Pharmacology-Metabolism): Doravirine
304	Doxapram metabolism in human fetal hepatic organ culture
305	Identification of doxapram metabolites using high pressure ion exchange chromatography and mass spectroscopy
306	Identification of metabolic pathways and enzyme systems involved in the in vitro human hepatic metabolism of dronedarone, a potent new oral antiarrhythmic drug. Pharmacol Res Perspect. 2014 Jun;2(3):e00044.
307	LC-MS/MS determination of dutasteride and its major metabolites in human plasma
308	Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett. 2005 Sep 28;227(2):115-24.
309	Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans Drug Metab Dispos. 2012 Dec;40(12):2250-5. doi: 10.1124/dmd.112.046888.
310	Oxidative metabolism of dehydroepiandrosterone (DHEA) and biologically active oxygenated metabolites of DHEA and epiandrosterone (EpiA)--recent reports
311	In Vitro Characterization of Ertugliflozin Metabolism by UDP-Glucuronosyltransferase and Cytochrome P450 Enzymes Drug Metab Dispos. 2020 Dec;48(12):1350-1363. doi: 10.1124/dmd.120.000171.
312	Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects Drug Metab Dispos. 2013 Feb;41(2):445-56. doi: 10.1124/dmd.112.049551.
313	The metabolism of estradiol; oral compared to intravenous administration J Steroid Biochem. 1985 Dec;23(6A):1065-70. doi: 10.1016/0022-4731(85)90068-8.
314	Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
315	Reactions of glutathione with the catechol, the ortho-quinone and the semi-quinone free radical of etoposide. Consequences for DNA inactivation. Biochem Pharmacol. 1992 Apr 15;43(8):1761-8.
316	U. S. FDA Label -Fenfluramine
317	Fentanyl Absorption, Distribution, Metabolism, and Excretion: Narrative Review and Clinical Significance Related to Illicitly Manufactured Fentanyl. J Addict Med. 2023 May 17. doi: 10.1097/ADM.0000000000001185.
318	Predictors of the Rate of Illicit Fentanyl Metabolism in a Cohort of Pregnant Individuals. J Addict Med. 2023 Jan-Feb 01;17(1):85-88. doi: 10.1097/ADM.0000000000001043.
319	Bupivacaine Metabolite Can Interfere with Norfentanyl Measurement by LC-MS/MS. J Appl Lab Med. 2022 Jun 30;7(4):854-862. doi: 10.1093/jalm/jfac009.
320	Simultaneous identification and quantitation of fluoxetine and its metabolite, norfluoxetine, in biological samples by GC-MS
321	DrugBank(Pharmacology-Metabolism):Fluticasone propionate
322	Ganaxolone
323	Reactive metabolite of gefitinib activates inflammasomes: implications for gefitinib-induced idiosyncratic reaction J Toxicol Sci. 2020;45(11):673-680. doi: 10.2131/jts.45.673.
324	Kinetics of glyburide metabolism by hepatic and placental microsomes of human and baboon
325	Identification of glyburide metabolites formed by hepatic and placental microsomes of humans and baboons
326	The single dose kinetics of chloroquine and its major metabolite desethylchloroquine in healthy subjects
327	Understanding the pharmacokinetics of anxiolytic drugs
328	The Role of Alcohol Dehydrogenase in Drug Metabolism: Beyond Ethanol Oxidation
329	The KEGG resource for deciphering the genome
330	2-Chloroacetaldehyde-induced cerebral glutathione depletion and neurotoxicity
331	Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism
332	Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes
333	In vitro biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1
334	Imipramine metabolites in blood of patients during therapy and after overdose
335	Deletion of the mouse Fmo1 gene results in enhanced pharmacological behavioural responses to imipramine
336	In vitro metabolism of indiplon and an assessment of its drug interaction potential
337	VMAT2 Inhibitors in Neuropsychiatric Disorders
338	Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients Drug Metab Dispos. 2000 Apr;28(4):423-33.
339	Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms. Eur J Drug Metab Pharmacokinet. 2021 Mar;46(2):317-324. doi: 10.1007/s13318-021-00675-3.
340	Pharmacokinetic evaluation of CYP3A4-mediated drug-drug interactions of isavuconazole with rifampin, ketoconazole, midazolam, and ethinyl estradiol/norethindrone in healthy adults. Clin Pharmacol Drug Dev. 2017 Jan;6(1):44-53.
341	Concomitant use of isavuconazole and CYP3A4/5 inducers: Where pharmacogenetics meets pharmacokinetics Mycoses. 2021 Sep;64(9):1111-1116. doi: 10.1111/myc.13300.
342	PharmGKB summary: ivacaftor pathway, pharmacokinetics/pharmacodynamics Pharmacogenet Genomics. 2017 Jan;27(1):39-42. doi: 10.1097/FPC.0000000000000246.
343	Identification of the cytochrome P450 enzymes involved in the metabolism of domperidone. Xenobiotica. 2004 Nov-Dec;34(11-12):1013-23.
344	Characterization of CYP3A isozymes involved in the metabolism of domperidone: role of cytochrome b5 and inhibition by ketoconazole. Drug Metab Lett. 2010 Apr;4(2):95-103.
345	Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther. 1996 May;277(2):805-16.
346	Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol Pharmacol. 1995 Feb;47(2):410-8.
347	Metabolic intermediate complex formation of human cytochrome P450 3A4 by lapatinib Drug Metab Dispos. 2011 Jun;39(6):1022-30. doi: 10.1124/dmd.110.037531.
348	Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases. Br J Pharmacol. 2011 Feb;162(4):989-99.
349	[Influence of CYP3A4/5 polymorphisms in the pharmacokinetics of levonorgestrel: a pilot study]. Biomedica. 2012 Oct-Dec;32(4):570-7.
350	Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions. Biochem Pharmacol. 1993 Feb 24;45(4):853-61.
351	Identification of unstable metabolites of Lonafarnib using liquid chromatography-quadrupole time-of-flight mass spectrometry, stable isotope incorporation and ion source temperature alteration
352	#N/A
353	Clinical pharmacokinetics of losartan. Clin Pharmacokinet. 2005;44(8):797-814.
354	Identification of sulfonyl-loxoprofen as novel phase 2 conjugate in rat
355	IgG and IgM Immunohistochemistry in Primary Biliary Cholangitis (PBC) and Autoimmune Hepatitis (AIH) Liver Explants
356	In vitro and in vivo pharmacokinetic characterization of mavacamten, a first-in-class small molecule allosteric modulator of beta cardiac myosin
357	Metabolism of megestrol acetate in vitro and the role of oxidative metabolites. Xenobiotica. 2018 Oct;48(10):973-983.
358	Effects of cytochrome P450 single nucleotide polymorphisms on methadone metabolism and pharmacodynamics
359	Disposition and metabolism of metronidazole in patients with liver failure
360	Metronidazole Metabolism in Neonates and the Interplay Between Ontogeny and Genetic Variation
361	Metronidazole: an update on metabolism, structure-cytotoxicity and resistance mechanisms
362	DrugBank(Pharmacology-Metabolism):Mycophenolate mofetil
363	Identification of human cytochrome P450 isozymes involved in the metabolism of naftopidil enantiomers in vitro. J Pharm Pharmacol. 2014 Nov;66(11):1534-51.
364	Characterization of Ca(2+)-antagonistic effects of three metabolites of the new antihypertensive agent naftopidil, (naphthyl)hydroxy-naftopidil, (phenyl)hydroxy-naftopidil, and O-desmethyl-naftopidil J Cardiovasc Pharmacol. 1991 Dec;18(6):918-25. doi: 10.1097/00005344-199112000-00020.
365	LABEL:Nalmefene
366	Disposition and biotransformation of the antiretroviral drug nevirapine in humans Drug Metab Dispos. 1999 Aug;27(8):895-901.
367	Differences in nevirapine biotransformation as a factor for its sex-dependent dimorphic profile of adverse drug reactions J Antimicrob Chemother. 2014 Feb;69(2):476-82. doi: 10.1093/jac/dkt359.
368	Sulfation of 12-hydroxy-nevirapine by human SULTs and the effects of genetic polymorphisms of SULT1A1 and SULT2A1. Biochem Pharmacol. 2022 Oct;204:115243. doi: 10.1016/j.bcp.2022.115243.
369	Cytochromes P450: a structure-based summary of biotransformations using representative substrates Drug Metab Rev. 2008;40(1):1-100. doi: 10.1080/03602530802309742.
370	Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. Biol Pharm Bull. 2005 May;28(5):882-5.
371	CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers Pharmacogenomics J. 2004;4(1):34-9. doi: 10.1038/sj.tpj.6500218.
372	Pharmacokinetics and metabolism of nifedipine Hypertension. 1983 Jul-Aug;5(4 Pt 2):II18-24. doi: 10.1161/01.hyp.5.4_pt_2.ii18.
373	Metabolic pro?ling of tyrosine kinase inhibitor nintedanib using metabolomics J Pharm Biomed Anal. 2020 Feb 20;180:113045. doi: 10.1016/j.jpba.2019.113045.
374	Oxidative bioactivation of nitrofurantoin in rat liver microsomes Xenobiotica. 2017 Feb;47(2):103-111. doi: 10.3109/00498254.2016.1164913.
375	In vitro metabolism of olaparib in liver microsomes by liquid chromatography/electrospray ionization high-resolution mass spectrometry Rapid Commun Mass Spectrom. 2020 Feb 15;34(3):e8575. doi: 10.1002/rcm.8575.
376	Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability Drugs Aging. 1995 Mar;6(3):243-62. doi: 10.2165/00002512-199506030-00007.
377	Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer. Clin Pharmacokinet. 2023 May 10. doi: 10.1007/s40262-023-01255-1.
378	Impact of genetic variation in CYP2C19, CYP2D6, and CYP3A4 on oxycodone and its metabolites in a large database of clinical urine drug tests. Pharmacogenomics J. 2022 Feb;22(1):25-32. doi: 10.1038/s41397-021-00253-5.
379	DrugBank(Pharmacology-Metabolism)Oxycodone hydrochloride
380	S73 \| METXBIODB \| metabolite Reaction Database from BioTransformer \| DOI:10.5281/zenodo.4056560
381	Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator. Drug Metab Dispos. 2010 Mar;38(3):376-85.
382	Value of preemptive CYP2C19 genotyping in allogeneic stem cell transplant patients considered for pentamidine administration. Clin Transplant. 2011 May-Jun;25(3):E271-5.
383	Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: a review J Psychiatry Neurosci. 1992 Nov;17(5):206-14.
384	DrugBank(Pharmacology-Metabolism)Phenobarbital
385	Simultaneous determination of prochlorperazine and its metabolites in human plasma using isocratic liquid chromatography tandem mass spectrometry Biomed Chromatogr. 2012 Jun;26(6):754-60. doi: 10.1002/bmc.1725.
386	Bioavailability and metabolism of prochlorperazine administered via the buccal and oral delivery route J Clin Pharmacol. 2005 Dec;45(12):1383-90. doi: 10.1177/0091270005281044.
387	Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5. Drug Metab Dispos. 2009 Feb;37(2):254-8.
388	Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro. Drug Metab Dispos. 2012 Sep;40(9):1778-84.
389	Identification of cytochrome P450 enzymes involved in the metabolism of FK228, a potent histone deacetylase inhibitor, in human liver microsomes. Biol Pharm Bull. 2005 Jan;28(1):124-9.
390	Determination of salmeterol, -hydroxysalmeterol and fluticasone propionate in human urine and plasma for doping control using UHPLC-QTOF-MS. Biomed Chromatogr. 2021 Aug;35(8):e5114. doi: 10.1002/bmc.5114.
391	Pharmacokinetics of salmeterol and its main metabolite -hydroxysalmeterol after acute and chronic dry powder inhalation in exercising endurance-trained men: Implications for doping control. Drug Test Anal. 2021 Apr;13(4):747-761. doi: 10.1002/dta.2978.
392	The salmeterol anomaly and the need for a urine threshold. Drug Test Anal. 2022 Jun;14(6):997-1003. doi: 10.1002/dta.2810.
393	Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe. Pharmacotherapy. 2009 Oct;29(10):1175-81.
394	Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. J Pharm Sci. 1998 Oct;87(10):1184-9.
395	Secnidazole. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic use in the management of protozoal infections and bacterial vaginosis Drugs. 1996 Apr;51(4):621-38. doi: 10.2165/00003495-199651040-00007.
396	Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism
397	In vitro biotransformation of sildenafil (Viagra): identification of human cytochromes and potential drug interactions. Drug Metab Dispos. 2000 Apr;28(4):392-7.
398	Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol. 2002;53 Suppl 1(Suppl 1):5S-12S. doi: 10.1046/j.0306-5251.2001.00027.x.
399	Erectile dysfunction drugs changed the protein expressions and activities of drug-metabolising enzymes in the liver of male rats. Oxid Med Cell Longev. 2016;2016:4970906.
400	Simvastatin Tablet, Film-Coated
401	Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
402	Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics Drug Metab Pharmacokinet. 2007 Oct;22(5):328-35. doi: 10.2133/dmpk.22.328.
403	Effect of Ticagrelor, a Cytochrome P450 3A4 Inhibitor, on the Pharmacokinetics of Tadalafil in Rats Pharmaceutics. 2019 Jul 20;11(7):354. doi: 10.3390/pharmaceutics11070354.
404	PharmGKB:Tamoxifen citrate
405	Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
406	Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
407	Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
408	Identification and biological activity of tamoxifen metabolites in human serum Biochem Pharmacol. 1983 Jul 1;32(13):2045-52. doi: 10.1016/0006-2952(83)90425-2.
409	PharmGKB summary: tamoxifen pathway, pharmacokinetics Pharmacogenet Genomics. 2013 Nov;23(11):643-7. doi: 10.1097/FPC.0b013e3283656bc1.
410	Pharmacokinetics and metabolism of temazepam in man and several animal species Br J Clin Pharmacol. 1979;8(1):23S-29S. doi: 10.1111/j.1365-2125.1979.tb00451.x.
411	Sigmoidal kinetic model for two co-operative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives. Biochem J. 1999 Jun 15;340 ( Pt 3):845-53.
412	Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica. 1996 Nov;26(11):1155-66.
413	Temsirolimus metabolic pathways revisited Xenobiotica. 2020 Jun;50(6):640-653. doi: 10.1080/00498254.2019.1678793.
414	LABEL:BSRELA- tenapanor hydrochloride tablet
415	DrugBank(Pharmacology-Metabolism)Teniposide
416	PubChem:Teniposide
417	Investigating the Contribution of Drug-Metabolizing Enzymes in Drug-Drug Interactions of Dapivirine and Miconazole
418	Retinoic acid metabolism and mechanism of action: a review
419	Human cytochrome P450s involved in the metabolism of 9-cis- and 13-cis-retinoic acids
420	A mass balance study to evaluate the biotransformation and excretion of [14C]-triamcinolone acetonide following oral administration J Clin Pharmacol. 2000 Jul;40(7):770-80. doi: 10.1177/00912700022009413.
421	Metabolic fate of a synthetic corticosteroid (triamcinolone) in the dog J Biol Chem. 1961 Apr;236:1038-42.
422	In Vitro Hepatic Oxidative Biotransformation of Trimethoprim Drug Metab Dispos. 2015 Sep;43(9):1372-80. doi: 10.1124/dmd.115.065193.
423	Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events Int J Impot Res. 2004 Jun;16 Suppl 1:S34-7. doi: 10.1038/sj.ijir.3901213.
424	High-performance liquid chromatographic method with amperometric detection employing boron-doped diamond electrode for the determination of sildenafil, vardenafil and their main metabolites in plasma J Chromatogr A. 2011 Nov 4;1218(44):7996-8001. doi: 10.1016/j.chroma.2011.09.001.
425	Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab Dispos. 2006 Aug;34(8):1317-27.
426	Vortioxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet. 2018 Jun;57(6):673-686.
427	Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats
428	Norzotepine, a major metabolite of zotepine, exerts atypical antipsychotic-like and antidepressant-like actions through its potent inhibition of norepinephrine reuptake

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.